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Capsule endoscopy (CE) is a first-line diagnostic tool for known or suspected small bowel 
bleeding (SBB), and its use has over time been expanded to include panenteric imaging. It 
offers advantages over conventional endoscopy in minimal invasiveness and ease of use. 
However several drawbacks remain including the lack of modalities other than imaging, 
inability to control or propel the capsule, lesser image quality compared to conventional 
endoscopy and labour-intensiveness of data interpretation. 
Aims and objectives 
This thesis aims to explore the ways in which use of CE can be optimised in the current clinical 
or “real world” context, focusing on its use in gastrointestinal bleeding and working within 
current resource and technological limitations.  
Methods 
A review and analysis of the existing literature was undertaken, examining the present state 
of CE technology and identifying current gaps in knowledge. Meta-analyses were undertaken 
examining the effectiveness of the two main methods of image enhancement in CE: the use 
of bowel preparation and currently available rudimentary computer-aided diagnosis. 
The following studies then looked into how to better select patients who should be prioritised 
for CE examination – a pertinent issue in today’s resource-stretched healthcare systems. A 
retrospective study was carried out to examine the effects of altering the timing of CE 
examination in patients referred for likely SBB, using cases carried out at our tertiary care 
centre over the past decade. Outcomes were compared between patients who had 
undergone CE following negative bidirectional endoscopies, or negative upper 
gastrointestinal tract endoscopy only. Furthermore, building on existing work, a second study 
was undertaken using a prospectively-designed database to collect multicentre data on 
findings and outcomes in young patients referred for CE with iron deficiency anaemia. This 
study investigated factors predictive of small bowel neoplasia in this patient group.  
Finally, the effect of image visualisation quality on diagnostic certainty was investigated. CE 
images were processed to alter image parameters, and the resulting images presented to an 
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international group of expert CE readers in order to determine thresholds for acceptable 
image quality and the effects of differing image quality in the parameters examined. 
Results 
Currently-available image enhancement techniques: 
(1) Use of bowel preparation: Laxative use did not improve the diagnostic yield of CE with 
odds ratio (OR) 1.1 for both overall and significant findings when comparing laxative use with 
pre-procedural fast only. However, subjectively-determined small bowel visualisation quality 
improved with the use of laxatives (OR 1.60 (95%CI 1.08–2.06)), NNT 14.  
(2) Use of suspected blood indicator (SBI): The overall sensitivity of SBI for bleeding or 
potentially bleeding lesions was 0.553, specificity 0.578, DOR 12.354. The sensitivity of SBI 
for active bleeding was 0.988, specificity 0.646, DOR 229.89.  
(3) Use of FICE digital image enhancement: Overall, the use of the three FICE modes did not 
significantly improve image delineation or detection rate in CE. For pigmented lesions only, 
FICE setting 1 performed better in lesion delineation and detection. 
Patient selection and CE pathways: 
The earlier use of CE in inpatients with melena or IDA, no signs of lower gastrointestinal 
pathology and negative UGIE resulted in shortened hospital stays, significant diagnostic yield 
from both small bowel and upper gastrointestinal tract, and two-thirds less unnecessary 
colon investigations without affecting clinical outcomes. 
In young patients (age <50 years) with IDA and negative bidirectional GI endoscopy, the 
overall diagnostic yield of CE for clinically significant findings was 32.3%. 5% of our cohort 
was diagnosed with SB neoplasia; lower MCV and weight loss were associated with higher 
diagnostic yield for significant SB pathology. 
Effects of visualisation quality on diagnostic certainty: 
Poor visualisation quality in all parameters affected mostly neoplastic lesions. Software to 
increase contrast and sharpen images can improve visualisation quality; smart frame rate 
adaptation could improve the number of high-quality frames obtained. Thoroughness in 




The data in this thesis show that CE could be employed earlier in the diagnostic pathway for 
patients presenting clinically with SBB, as an effective diagnostic and triage tool in the semi-
acute setting. Although the overall diagnostic yield of CE is lower in younger patients, young 
patients with IDA and no significant findings on bidirectional endoscopy are also more likely 
to have significant small bowel findings, and should perhaps be referred preferentially for CE. 
This would help increase the efficiency of resource utilisation. 
Of the currently available image enhancement techniques in CE, digital image enhancement 
and diagnostic tools such as SBI and FICE remain of limited validity; however they show the 
most promise for vascular lesions and active GI bleeding, which supports their use in the 
acute to semi-acute setting to improve efficiency of CE reading. Image enhancement with 
both laxatives and digital means is the most crucial when patients are suspected of having 







Capsule endoscopy (CE) involves a small camera in a pill, which is swallowed by patients and 
takes several images as it passes through the gut to be excreted naturally. It is used to 
investigate the small bowel, and is primarily used to look for sources of bleeding and areas 
of inflammation, but is also now used to image the whole gut. This thesis examines ways of 
optimising the use of CE in gastrointestinal bleeding. 
Ways to enhance CE image quality: Laxatives are commonly used to clear the bowel prior to 
CE. Analysis of data from several previous studies showed that although laxative use 
improved visualisation quality in the small bowel by a factor of 1.5x, it did not increase 
diagnostic yield. Suspected blood indicator (SBI) software automatically selects frames with 
areas of red pixels to help pick up areas of bleeding. Analysing data from several published 
studies, SBI was found to have sensitivity of 55% for bleeding or potentially bleeding lesions. 
However the sensitivity for active gut bleeding was much higher at 98.8%. On the other hand, 
digital colour alteration with FICE did not significantly improve image visualisation quality or 
image detection rate. 
Patient selection and CE pathways: 
Examining data collected at a university teaching hospital showed that the earlier use of CE 
in inpatients with suspected small bowel bleeding resulted in shortened hospital stays and 
two-thirds less unnecessary colon investigations, without affecting patient outcomes in our 
patient group.  
Previous research has shown that young patients (age <50 years) with anaemia are more 
likely to have significant small bowel findings on CE. A larger group of such patients was 
collected across several teaching hospitals. In young anaemic patients, CE picked up 
significant findings in was 32.3%. 5% of this group had small bowel tumours. Patients with 
lower MCV and weight loss were more likely to have significant findings. 
Effects of visualisation quality on diagnostic certainty: CE images were modified to reduce 
visualisation quality in a stepwise manner, focusing on the parameters of image opacity, 
blurriness and contrast. Expert CE readers were asked determine if they could make a 
confident diagnosis from these images. Images of small bowel tumours were most affected 
by poor visualisation quality, compared to images of bleeding vessels or bowel inflammation.  
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This thesis shows that CE can be an effective diagnostic and triage tool in patients with 
suspected small bowel bleeding. Although the overall diagnostic yield of CE is lower in 
younger patients, young patients with anaemia are also more likely to have significant small 
bowel findings, and should perhaps be referred preferentially for CE. This would help 
increase the efficiency of resource utilisation. Of the currently available image 
enhancement techniques in CE, digital image selection and enhancement tools remain of 
limited usefulness. They are most useful when there is active bleeding in the gut, which 
supports their use in the acute to semi-acute setting to improve efficiency of CE reading. 
Image enhancement with both laxatives and digital means is the most crucial when patients 
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Chapter 1 Introduction 
Capsule endoscopy (CE) is a prime imaging modality for the small bowel (SB) introduced to 
routine clinical practice in the mid-2000s. Images are obtained by a micro-camera as the 
capsule is propelled through the gastrointestinal (GI) tract by peristalsis; these images are – 
in most capsule models – transmitted wirelessly to an external receiver, producing a video 
which is then read and interpreted by clinical staff1. Since its introduction, CE has become an 
invaluable diagnostic tool due to its minimal invasiveness, safety, and ease of use for both 
clinicians and patients.  
 
1.1 Overview of capsule examination 
 1.1.1 CE process 
A capsule examination involves a pill-sized and shaped camera which is swallowed by the 
patient in order to image the GI tract. The camera takes multiple sequential images as it 
passes through the GI tract, usually at a rate of several frames per second. In most models 
the images are transmitted remotely to an external recorder which the patient must carry on 
their person for the duration of the examination (see Table 1.1 for a detailed summary of 
capsule models). The capsule records for a period of up to 12h, following which the recording 
device is retrieved and the captured images are downloaded to a capsule reading software 
platform. The images are strung together to achieve a video of the GI tract, which is then 
read and reported. 
Conventionally, capsule reporting involves identification of key anatomical landmarks 
allowing the footage to be divided into oesophageal, gastric, small bowel, and colonic 
segments. The landmarks are: first gastric image, first duodenal image, and first caecal image 
or ileocaecal valve (ICV). Usually, some comment is made regarding quality of bowel 
preparation, as this influences diagnostic certainty and overall clinical usefulness of the 
examination. Reporting of a single CE examination is usually estimated to take 30-90 minutes, 
depending on complexity of the examination and reader experience2,3. 
At present there remain few guidelines to standardise the capsule reading and reporting 
process4, although recent recommendations have been made regarding credentialing for CE 
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reading and reporting5–7. The evidence that these recommendations are based on is 
moderate at best. 
 
 1.1.2 Indications for CE 
At present, CE is the main mode of SB investigation, as it is able to access areas beyond the 
reach of conventional upper GI tract endoscopy (UGIE) and colonoscopy in a minimally-
invasive manner – for the oesophagus, stomach and colon, conventional endoscopy remains 
the gold standard due to the ability to both diagnose and treat, as well as the ability to control 
the endoscope within the body. Double-balloon enteroscopy, although considered the gold 
standard for SB visualisation, is a far more invasive and laborious process with proportionally 
greater risks to the patient and greater demand on resources such as time, medical 
equipment and manpower. 
The strongest clinical indication for CE, which makes up the bulk of CE referrals, is for 
investigation of suspected small bowel bleeding (SBB), which is currently defined as has 
previously been referred to as obscure GI bleeding (OGIB) (see section 1.4). The next most 
common indication for CE is for investigation of suspected SB inflammation, usually 
suspected Crohn’s Disease (CD), and similarly for repeat SB visualisation in patients with 
known CD, to monitor disease progress and response to treatment. 
A much less common but nonetheless crucial indication for CE is the investigation of 
suspected SB malignancy. Although SB tumours are rare and account for only 1-3% of primary 
GI malignancies8, their rarity and usually nonspecific presentations mean they tend to be 
diagnosed late, with approximately 50% having metastasised by the time of diagnosis9. Of 
note, iron deficiency anaemia (IDA) forms a significant proportion of referrals for patients 
who are eventually diagnosed with SB malignancies. Previous case series and reports have 
estimated that IDA accounts for 60-100% of indications for SB cancers diagnosed via CE; this 






1.2 Imaging capsules currently available 
Overall, CE presents certain advantages over more invasive endoscopic techniques, including 
its safety, ease of use and feasibility11–13; therefore, in more recent years the indications for 
CE have expanded to include upper GI tract imaging with oesophageal and gastric capsules, 
colon CE and “panenteroscopy” with the Crohn’s capsule14. 
For the purposes of this thesis I have included only visual/imaging capsule models. 2 non-
imaging capsules are currently commercially available - Motilis®15 and SmartPill®16 - which 
are marketed for investigation of gut motility and physiology, but these are not discussed 
here due to their vastly different nature. Table 1.1 provides a summary of the currently 








Table 1.1: Current commercially available capsule models and their specifications 



























use of capsule 
SB imaging Oesophageal 
imaging 





Apart from MiroCam® Navi 
(part of MC1000 series) for 
stomach imaging 




Mass(g) 3.0 2.9 2.9 2.9 3.25 Ns 3.3 <6 ns <5 
Dimension(mm) 11x26 11x26 11x31 11.6x32.3 10.8x24.5 10.8x30.1 11x26 13x27.9 11x31 28x12 
Battery(h) ≥8 0.5 10 10 12 12 8±11 15 ≥8 
Illumination 4 LED 2x4 LED 2x4 LED 2x4 LED 6 LED 6 LED 6 LED 16 LED Ns 
Field of view(°) 156 172 172 168 170 160 140±10 360 140 
Depth of field(mm) 0-30 0-30 0-30 0-30 7-20 0-20 0-35 0-30 0-30 
Number and type 
of cameras 
1xCMOS 2xCMOS 1xCMOS 2xCMOS 1xCCD 1xCMOS 4xCMOS 1xCMOS 
Image  
Resolution 
320x320 256x256 ns Na 320x320 1920x 
1080 
QVGA VGA N/A 480x480 
Image Sampling 
rate (fps) 































Yes No Yes Yes No No No Yes No 
Need for external 
receiver 
Yes Yes Yes Yes No Yes 
Data transmission RF Electric field propagation RF RF On-board 
EPROM flash 
RF 




1.3 Use of CE in small bowel bleeding (SBB) 
1.3.1 Definition of SBB 
SBB, defined as recurrent and/or persistent GI bleeding from a source which remains 
unidentified following negative bidirectional GI endoscopy, is currently the strongest and 
most common clinical indication for performing CE17. It presents as iron deficiency anaemia 
(IDA) and/or melaena18,19, and has previously been referred to as OGIB, a term recommended 
now only for patients in whom the source of bleeding remains unclear following GI 
investigation20. 
1.3.2 Current guidelines 
Current guidelines recommend the use of CE following negative bidirectional GI endoscopy 
in patients with SBB20–22. However, the available evidence underlying these guidelines is 
classed as “moderate” at best by the European Society for Gastrointestinal Endoscopy 
(ESGE), and few existing studies have evaluated the accuracy parameters (e.g. sensitivity, 
specificity, positive predictive value and negative predictive value) of CE21. This may be due 
to the lack of a suitable and accessible “gold standard” for comparison – although the ESGE 
suggests that intraoperative endoscopy is the ideal standard for evaluation of CE, such a 
study is relatively un-feasible to carry out. 
Overall, the diagnostic yield of CE in OGIB/SBB is estimated to be 60-70%20,21, implying that a 
significant proportion of 30-40% patients remain undiagnosed following CE. Previous work 
carried out prior to initiation of this thesis has however shown that CE has clinical value if 
even for prognostication – patients with negative CE are half as likely to re-bleed compared 
to those with positive findings on CE19. 
 
1.4 Use of CE in iron deficiency anaemia (IDA) 
 1.4.1 Definition of IDA 
Anaemia is defined by the World Health Organisation as haemoglobin concentrations (Hb) 
below 130mg/L in men and 120mg/L in non-pregnant women over 15 years old; however the 
definition of iron deficiency varies in the literature and is generally based on markers 
including mean corpuscular volume (MCV), serum iron and transferrin levels, transferring 
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saturations and ferritin. Current guidelines recommend that barring the presence of 
significant overt non-GI blood loss, GI investigation is warranted in all male and 
postmenopausal female patients23. 
Patients who present with isolated IDA and no obvious or overt signs of GI bleeding are a 
particular subset of patients with SBB who often present diagnostic and management 
difficulties. In the developed world, IDA in general is estimated to affect about 5-10% of 
premenopausal women and 2-5% of men and postmenopausal women24,25. Therefore, it 
accounts for up to 13% of GI referrals, representing a significant burden of GI disease and 
gastroenterologists’ workload23,26. Despite the increased uptake of bidirectional GI 
endoscopy in the diagnostic evaluation of IDA, a significant 30-50% of patients remain 
undiagnosed26. 
In these patients, guidelines based on moderate to weak evidence23 suggest an initial trial of 
treatment with iron supplementation. Further direct SB visualisation is not recommended 
unless there are symptoms suggestive of SB disease or in refractory IDA; however anecdotally 
it is now routine to perform CE in patients following negative bidirectional endoscopy, where 
SBB is suspected. 
 
 1.4.2 IDA and patient demographics 
Previous CE studies have shown that the aetiology of GI blood loss differs with patient 
demographics. Although younger patients (conventionally defined as age 50 years and 
below) form a smaller proportion of patients referred for CE with suspected SBB, the small 
amount of available evidence suggests that they are more likely to have significant findings. 
Young patients are more likely to bleed from SB malignancies, Dieulafoy lesions, Meckel’s 
diverticula, polyps or Crohn’s Disease (CD). Conversely, those older than 40 are more likely 
to have angioectasias or non-steroidal anti-inflammatory drug (NSAID)-induced ulceration27–
29. SB tumours (or malignancies) have a prevalence of 3-9% in patients undergoing SB 
evaluation30,31 and although uncommon, they are of particular importance due to their poor 
prognosis. Furthermore, an increasing incidence of SB malignancy has been documented 
over the past few decades32,33. 
Therefore, under the current guidelines, younger patients may be at risk of delayed diagnosis, 
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which could adversely impact outcomes34. Moreover, to the best of our knowledge, only a 
few studies focusing on young IDA patients undergoing SB evaluation are available to 
date28,29,35. Therefore questions raised include whether younger patients presenting with SBB 
should be fast tracked for CE, as well as how to assess bleeding potential and/or clinical 
significance of small bowel findings in order to guide further management. 
 
 
1.5 Use of CE in GI bleeding outside of the SB 
CE is usually performed non-acutely for the aforementioned indications as an outpatient 
procedure. Commonly, such patients tend to be admitted and stabilised (if necessary), 
investigated with an urgent upper GI endoscopy, and discharged to await further 
investigation. However, there is emerging evidence that performing CE closer to the index 
bleeding episode increases its diagnostic yield, within the suggested time frame of 14 days. 
More recent work suggests that in SBB the maximum diagnostic yield for CE is achieved 
within the first 72h of presentation36. This is corroborated by studies showing that for the 
same indications, inpatient CE has a higher diagnostic yield compared to outpatient 
procedures 37–39. Unfortunately there is overall scarce data on the inpatient use of CE (Table 
1.2). 
Although current practice varies, guidelines generally suggest performing CE in patients 
presenting acutely with suspected SBB only following both negative upper and lower GI 
endoscopy (i.e. negative bidirectional endoscopy). Performing colonoscopy in the acute 
setting is a demanding task both for the patient and clinician, and is often limited by the 
quality of bowel preparation and patient fitness or tolerance. At our large tertiary care 
hospital, there has recently been a trend for performing CE following a negative index upper 
GI endoscopy (UGIE) alone, with anecdotal evidence that by doing so unnecessary 
colonoscopies have been avoided in a proportion of patients. This is an area which perhaps 
merits further investigation, which this thesis therefore aims to explore.  
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Table 1.2: Summary of previous studies on inpatient use of CE 
Authors, 
Yearref 






NS Inpatients: 22 
Outpatients: 
133 
CE incomplete in 50% of 



















nongastric passage and 
incomplete CE more likely 
in inpatients. 
Inpatients had longer GTT, 
were more likely to be 
male and have overt 
bleeding. 









Predictive factors for 
positive CE: males, >60 
years old, overt bleeding, 
inpatients 










Inpatients were older, 
more likely to have overt 
bleeding, and active 
bleeding was more 
commonly found in 
inpatients. 
CE completion rate 
significantly lower in 
inpatients and patients 
with GI bleeding; 
prolonged GTT and SBTT 
in inpatients. 
Results amplified when 
looking only at ICU 
inpatients vs general ward 
patients. 











having CE for 
overt OGIB) 
Early use of CE within 3 
days of admission 
associated with higher 
diagnostic yield, 
therapeutic intervention 
rate and reduced length 
of stay. 
Abbreviations: CE capsule endoscopy; GTT gastric transit time; ICU intensive care unit; OGIB obscure 





1.6 Limitations of CE 
 1.6.1 Limited scope for enhancement of visualisation quality 
Many limitations remain which curtail the wider adoption and use of CE. A significant 
limitation is that CE remains an entirely visual mode of investigation in the context of GI 
bleeding – any type of multimodal capsule has yet to progress far beyond the developmental 
or experimental stage into mainstream usage.  
The overall positive diagnostic yield for SB disease using CE is approximately 60%41. The 
largest concern, as in most modes of investigation, is that the capsule may miss crucial lesions 
such as ulcers and submucosal tumours and/or other SB malignancies42–45. Bar the Ankon 
gastric capsule, the vast majority of commercial CE devices – and all SB capsules – are 
passively propelled by gut peristalsis. Visualisation of the entire length of SB is achieved in 
80–90% of patients21,46, while the lack of control over capsule propulsion leads to an 
estimated 30% of discrete lesions being missed, especially when there is increased gut 
motility or if an image of a lesion is captured in only one brief frame47,48. 
Most developments and variations in CE have focused on changing the configuration of 
cameras, for example putting cameras around the body of the capsule rather than on the 
end, as in Capsocam, or putting two heads on a capsule as in the Pillcam® Colon and Crohn’s 
capsules. Although proprietary capsule reading software includes various methods of post-
capture image enhancements such as the ability to increase contrast (common to almost all 
capsule reading platforms), to enhance certain wavelengths of light (as in FICE imaging), or 
to make shades of red stand out more (as in the OMOM software), all these methods depend 
heavily on the quality of the original image captured by the cameras. 
Therefore, the utility of CE is also limited by capsule size, which affects the amount of battery 
and processing power which can be included. At present, CE imaging quality has yet to meet 
the standards of conventional endoscopy, let alone enhanced imaging, even though battery 
life, resolution and field of vision have improved over time. Despite substantial improvement 
in image quality in recent years, particularly in image resolution, the image pixelation of 
capsule models remains disappointingly low49,50, especially when compared with that of 




 1.6.2 Capsule reading and reporting 
Capsule reading and reporting is a time- and labour-intensive process. A single CE 
examination generates lengthy video footage which makes it time and labour-intensive to 
interpret; this affects the utility of an examination, especially when considering its use in the 
acute to semi-acute setting. 
Computer-assisted diagnosis remains elusive. Although software has been developed to help 
with identification of pathology, these methods remain mostly unvalidated and unproven by 
larger, robust studies. There are two main types of software available to aid CE reading: (1) 
image/video enhancing software to improve the visualisation and pickup of pathology51, and 
(2) image selection software which selects frames from a CE video for further review, thus 
reducing the number of frames or segments the human CE reporter has to view. 
(1) Image enhancing software 
Examples of image enhancing software include basic image adjustments common to all 
capsule reading and reporting software– mainly brightness and contrast. Proprietary 
software includes FICE and blue mode for PillCam® and ALICE for Mirocam® (which also offers 
high dynamic range (HDR) capability).  
Blue mode has previously been discussed52–55 whilst there is scant data available on ALICE56 
and QuickView57–60; therefore in this thesis, I have focused on FICE and SBI, which have the 
largest body of data and represent examples of the two main groups or types of software. 
(2) Image selection software 
Examples of  image selection software include the SBI, PillCam®’s QuickView and Mirocam®’s 
Express View option. Also in their early stages are novel machine learning algorithms for the 
automated detection of pathology in endoscopic images61,62; again, such technology has yet 
to become fully developed, well-validated and readily available. 
Because CE is at present an entirely visual mode of investigation, current developments to 
improve its utility have focused on not only improving image quality but also increasing the 
amount of data generated from a single investigation (for example with increased and 
adaptive frame rate, longer battery life and larger data storage), with the belief that 
increasing the amount of information obtained will improve its diagnostic abilities. 
Conversely, this potentially creates a form of information overload and reader fatigue, 
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therefore making it all the more important that computer-aided diagnosis becomes available 
and reliable. Developmental computer-aided diagnostic software has already proven useful 
in other modes of endoscopy, including the use of deep learning and convolutional neural 
networks for polyp detection in colonoscopy, and also for optical biopsy to aid identification 
of higher risk polyps and early gastric cancer63. Indeed, CE may prove ideal for the 
development of such software precisely because of the vast amounts of often quite-
repetitive data generated in a single capsule examination. 
Overall, however, until more efficient ways of CE reading and reporting can be developed 
and made mainstream, the more judicious selection of patients undergoing CE may improve 
the efficiency of this mode of investigation, although unanswered questions about when and 
how to best employ CE remain21,64. 
 
 1.6.3 Need for bowel preparation 
Finally, bowel preparation prior to CE examination is still required, to reduce the amount of 
luminal content and ensure clear mucosal views. However, the optimal pre-CE bowel 
preparation remains a much-debated topic amongst users worldwide. Several regimes have 
been proposed using different laxatives, dosages and administration timings; conversely, 
other clinicians prescribe a clear liquid diet for 24-48h prior to CE with a pre-CE overnight 
fast, without the use of laxatives. 
Those in favor of laxative preparation argue that laxatives improve image quality and SB 
mucosal visualisation, therefore potentially increasing diagnostic yield65,66. Furthermore this 
appears to offer the clinician better control over bowel emptying. Conversely, those 
advocating the use of only a clear liquid diet and pre-procedural overnight fast believe that 
this achieves adequate visualization with superior patient acceptability67. Laxative bowel 
preparation is often the most unpleasant part of endoscopic investigations for patients, and 
is also particularly difficult for frailer patients who may struggle to cope with the diarrhoea, 
consequent dehydration and potential electrolyte imbalances. However, frail patients may 
also more often be considered for CE as opposed to conventional endoscopy due to its 
minimally-invasive nature, lack of requirement for sedation and east of use. 
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Perhaps due to the controversial nature of this topic and wide range of clinical opinions, a 
good number of meta-analyses have been carried out68–71. However, several more articles 
with contradictory conclusions have since been published and a re-examination of the data 






Chapter 2 Aims and Objectives 
This thesis aims to explore the current limits of CE in the clinical or “real world” context, 
examining ways in which its use can be optimised in conventional clinical settings. This is 
perhaps especially pertinent in the context of increasingly stretched healthcare systems with 
limitations on both monetary resources and manpower. 
For the purposes of this thesis, I have elected to focus on the indication of GI bleeding as it 
forms the largest group of patients referred for CE. 
 
The following areas were identified for further investigation: 
2.1 Current image enhancement technologies in CE 
The currently-available methods for image enhancement in CE – both clinical, using bowel 
preparation, and digital – will be explored to determine their effectiveness and identify 
specific areas for future development. 
For digital image enhancement methods, I have chosen to focus on FICE as the currently most 
widely-studied example of image enhancement software and SBI as an example of 
frame/image selection software. 
The use of bowel preparation is also investigated as this is the main way in which image 
quality can be clinically influenced and is also a topic currently under some debate amongst 
CE users. 
2.2 Use of CE in the acute/semi-acute setting for GI bleeding 
This thesis will then examine the role of CE in the diagnostic pathway for patients presenting 
acutely with potential SBB. This chapter focuses on patients with signs of upper- to mid-GI 
tract bleeding (melaena and/or IDA), following negative UGIE. 
This is based on the clinical experience at our tertiary care centre, where an early CE 
examination has sometimes been used as both a diagnostic and triage tool in patients who 
present with signs of more proximal GI bleeding but no significant findings on upper GI 




2.3 Patient selection and prioritisation for CE examination 
As previously discussed, in elderly patients with signs of SBB the most likely diagnosis is that 
of vascular lesions in the SB, and therefore a conservative approach is sometimes more 
appropriate in these patients. Conversely, younger patients presenting with isolated IDA are 
a relatively small but significant group of patients who present diagnostic difficulties. 
Also building on previous work carried out at our centre which suggested that younger 
patients with IDA were more likely to have significant SB pathology, this next section aimed 
to investigate CE findings and outcomes in a larger, multicentre group of young patients 
referred for CE with iron deficiency anaemia, and especially to identify factors predictive of 
significant small bowel findings in this patient group. 
2.4 Effect of image and visualisation quality of CE images 
Much has been said about how CE is limited as it is a solely visual mode of investigation, and 
there is much discussion about methods to improve the quality of images obtained. However, 
there is at present little standardisation in how to quantify image quality in CE reporting; this 
presents certain barriers to transmission of information for both clinical and research 
purposes. I therefore aimed to examine the contribution of various image parameters to the 




Chapter 3 Systematic review and meta-analysis: FICE image enhancement in CE 
Chapters 3 to 5 detail meta-analyses carried out to investigate the currently available 
methods for image enhancement in CE. In this chapter, I aim to establish the clinical 
effectiveness of FICE, which is perhaps the most widely-available and -used digital image 
enhancement software in CE reading and reporting, and therefore a good representation of 
this class or type of image enhancement techniques.  
 
3.1 Introduction: FICE 
Flexible spectral imaging color enhancement (FICE; also Fujinon Intelligent Chromo 
Endoscopy; Fujinon, Saitama, Japan) is a digital processing algorithm which takes white-light 
endoscopy (WLE) images and mathematically processes the image by emphasizing certain 
ranges of wavelengths. Three single-wavelength images can be selected and assigned to red, 
green, and blue (RGB) monitor inputs to display a composite color-enhanced image 
(Table 4.1, Figure 4.1)51. FICE virtual chromoendoscopy is hypothesized to enhance surface 
patterns, improving visualization and detection of mucosal lesions72. FICE has been applied 
to endoscopy of the upper and lower GI tract, as well as in double-balloon enteroscopy73,74, 
with the aim of increasing detection of neoplastic lesions. However, there remains a lack of 
conclusive evidence for its clinical effectiveness in enhancing lesion visualization and 







Table 3.1: Wavelengths (in nm) for each of the FICE modes used in RAPID® capsule reading 
software 
Mode Red Green Blue 
FICE 1 595 540 535 
FICE 2 420 520 530 




Figure 3.1: (a) Angioectasia and (b) SB ulcer, as visualised with white-light imaging and FICE 





(a) Angioectasia images 
Top L: Original image 
Top R: FICE setting 1 
Bottom L: FICE setting 2 
Bottom R: FICE setting 3 
(b) SB ulcer images 
Top L: Original image 
Top R: FICE setting 1 
Bottom L: FICE setting 2 




 3.2.1 Search strategy 
A comprehensive literature search was conducted using the PubMed and Embase databases 
(January 2000 to November 2015). The search was performed on December 12 2015. In order 
to capture as many full-text articles and abstracts as possible, a broad search strategy was 
employed, using the terms “capsule endoscopy,” “small-bowel,” “FICE,” and 
“chromoendoscopy” in various combinations. The initial search was performed with no 
limitations. Primary selection was based on titles and abstracts; further selection involved 
reading the full texts of any relevant publications (Figure 3.2). 
For a study to be included for meta-analysis, the following inclusion criteria were defined: (a) 
complete articles published in English; (b) articles where CE was used to investigate small-
bowel pathology only; and (c) articles where one or more of the three FICE modes was used 
on CE images and/or videos. Studies had to have investigated: (i) changes in image 
delineation or (ii) changes in lesion detection, using FICE. 
Data extraction and quality control were performed independently by myself and a second 
reviewer, so that cross-checking could be carried out. Data from included articles were 
extracted into a predefined data collection sheet for collation and comparison. A third 
reviewer, expert in capsule endoscopy and the content material, was involved if there was 
any uncertainty about the data or discrepancies. When additional data were required, 
primary (first and/or senior) authors of the specific manuscript(s) were contacted by email 
with relevant questions. 
































Literature search of PubMed and Embase databases. 
References were cross-checked; no further studies were identified via references. 
Studies identified: 54 
Full text read: 29 
Initial exclusions based on abstract and/or title: 25 
Reviews/editorials/letters/opinion papers: 17 
Not written in English: 5 
Studies dealt only with blue mode and not FICE: 3 
Studies included in final analysis: 13 
Further exclusions of full text articles: 16 
Data irrelevant on reading full text: 13 
Outcome measure was not delineation or 
detection of lesions: 2 
Exploratory study with no statistical analysis: 1 
Studies measuring 
delineation only: 3 
Studies measuring 
detection only: 9 
Studies measuring both 
delineation and detection: 1 
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3.2.2 Outcome measures 
Lesion delineation 
This was defined as the pooled rate of improvement in lesion visualization based on reader 
rating (individual or average), as measured against the original WLE image for: (a) each of the 
FICE modes, and (b) the two main pathological findings consistently presented across all 
studies: angioectasias and small-bowel mucosal ulcers/erosions.  
Images where visualization was deemed similar to or worse than with WLE were grouped 
together as “lack of improvement.” 
Lesion detection 
This outcome measure examined whether there was any significant difference between the 
average number of lesions detected across the three FICE modes and the white-light mode, 
for angioectasias and mucosal ulcers/erosions. This technique was used in studies where 
each CE video was viewed only once by one reader. 
3.2.3 Statistical analysis 
Data on the DY of CE were extracted, pooled, and analysed. Where sufficient data were 
available for analysis (i.e. 3 or more studies available with relevant data), pooled results with 
corresponding 95% CIs were derived using the fixed effects model (Mantel–Haenszel 
method) unless significant heterogeneity was detected, in which case, a random effects 
model (DerSimonian–Laird) was used. The Q statistic of χ2 test and I2 were used to estimate 
the heterogeneity of individual studies contributing to the pooled estimate. I2 values were 
used to evaluate whether the differences across the studies were greater than could be 
expected by chance alone. A P value <0.05 suggests the presence of heterogeneity beyond 
what could be expected by chance alone. I2 values of 20%–50% or of >50% suggest moderate 
and high heterogeneity, respectively. Forest plots were constructed for visual display of 
individual study and pooled results76. 
Sensitivity analyses were generally conducted firstly by examining forest plots to identify 
significant outliers, and by systematic exclusion of studies to assess whether this caused 
significant shifts in results. Further analyses of relevant subgroups were also attempted if 
adequate data were available. 
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Repeated-measures analysis of variance (ANOVA) was used to measure the difference in 
lesion detection between WLE and the three FICE modes based on the findings from the 
videos in WLE mode and using FICE settings 1–3. The F statistic was used to determine 
significance in repeated-measures ANOVA. P < 0.05 for the F-statistic was considered 
statistically significant77. Statistical analysis was performed by using the Metan package of 
STATA version 12.1 (StataCorp, College Station, Texas, US).  
3.2.4 Assessment of study bias 
Methodological quality and potential bias of the included studies was evaluated by using the 
QUADAS-2 scale78. The use of FICE was the “index test” and CE imaging or video review under 





3.3 Results and meta-analysis 
 3.3.1 Search results and included study characteristics 
The initial search yielded 54 publications (Figure 3.2) of which 39 were excluded for the 
following reasons: articles were reviews/editorials/letters/opinion papers (n = 17); data 
found to be irrelevant on reading of full text (n = 13); not in English language (n = 5); studies 
which dealt exclusively with other chromoendoscopy techniques (e.g. Blue mode) and not 
FICE (n = 3); outcome measure not delineation or detection of lesions (n = 2)79,80; study was 
exploratory with no statistical analysis (n = 1)81.  
Eventually, 13 studies were included (Table 3.2)54,73,90–92,82–89. The countries of origin for the 
studies were: Japan (n = 7)73,82,83,86–89, Portugal (n = 4)84,85,90,92, Belgium (n = 1)91, and the 
United Kingdom (n = 1)54. All studies were conducted using PillCam®SB 1 and/or 2 
(Medtronic, Minnesota, USA) and most used experienced readers, usually defined as having 
read >100 capsule endoscopies. 
Two sets of studies were identified as coming from the same hospitals. Two studies from the 
Imagawa et al. group were used for two separate analyses, one for delineation82 and one for 
detection73. Therefore there was no overlap in the data used in these two studies. Another 
three studies84,90,92 were carried out by the same group of researchers at the same center; 
these were confirmed by direct contact with one of the study authors to have used 








Table 3.2 (a): Summary of studies measuring lesion delineation as an outcome 






FICE 1 FICE 2 FICE 3 
Angioectasias Improved Similar Worse Improved Similar Worse Improved Similar Worse 
Krystallis, 201154 UK PillCam® 
SB1/2 
2 1 moderate 
(>50 CEs), 1 
experienced 
(>500 CEs) 





5 NS 23 20 3 0 20 2 1 1 22 0 




152 Outcome measured by average of 
VAS from readers with positive 
scoring for “improved” and 
negative scoring for “worse”; 
breakdown not specified. 
Average VAS for FICE 1: 72.7±5.2 
Average VAS for FICE 2: 74.0±14.9 Average VAS for FICE 3: 58.7±14.9 








60 22 6 32 2 8 50 2 4 54 
Imagawa, 2011 
(GIE)82 
47 26 19 2 12 32 3 0 34 13 
Sato, 201483 88 Average VAS for FICE 1: 72.9±5.4 Average VAS for FICE 2: 67.9±5.7 Average VAS for FICE 3: 53.5±6.5 
Cotter, 201484 49 31 12 6 28 10 11 12 18 19 




Table 3.2 (b): Summary of studies measuring lesion detection as an outcome 
































50 1 reader for 
WL, 1 for FICE 
NA 17 48 45 24 
Duque, 201285 Portugal PillCam® 
SB2 
4 Experienced 20 1 reader for 
WL, 1 for FICE 





3 NS 24 All videos and 











2 Experienced 81 All videos and 






2±1.4 1.3±0.5 4±1.2 
Sakai, 201288 Japan PillCam® 
SB2 
4 No previous 
CE experience 
12 Crossover*; 
each video in 
each mode 
read once only 
60 26 40 38 31 
Konishi, 201489 Japan PillCam® 
SB2 
5 Experienced 10 All videos and 







0.92±0.2 0.72±0.18 0.74±0.2 
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50 Crossover NA 17 24 33 18 
Boal Carvalho, 
201690 
Portugal NS 4 Experienced 
(>100 CEs) 





NA 32 40 54 51 















3.3±2.3 3.6±3.4 1.9±1.2 
Sakai, 201288 82 38 62 60 20 




















Sato, 201483 NA 28 22 41 24 
Boal Carvalho, 
201690 
17 15 17 NA NA 
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Studies where Saurin Score used (types of lesions not specified) 










NA All 3 FICE modes used together. 
P0: 20 (reader 1), 27 (reader 2) 
P1: 37, 55 
P2: 60, 72 























*Example of “crossover” study: Reader 1 viewed group A of videos under WL only, then group B under FICE 1. Reader 2 viewed group A under FICE 1 only and 
group B under WL only. Therefore each video is seen by only 1 reader for each mode. 




3.3.2 Lesion delineation 
Improvement in delineation of capsule endoscopy images of lesions was investigated in 4 
studies54,82–84. Of these, 1 study83 was excluded from further analysis; the use of a visual 
analogue scoring system meant that the results could not be entered into the meta-analysis.  
Only the use of FICE setting 1 on images of angioectasias appeared to produce a higher rate 
of improved delineation, with 89% of images considered improved, whereas 45% of images 
of ulcers/erosions were considered improved using FICE 1. FICE 2 improved delineation in 
43% of images of angioectasias. For images of angioectasias in FICE 3 and images of 
ulcers/erosions in FICE 2 and 3, negligible proportions of images were considered to show 
improved delineation (Table 3.3, Figures 3.3 and 3.4).  
Heterogeneity of studies was high with I2 >90% in 4/6 analyses carried out.  
 
Table 3.3: Pooled proportions of “improved” images for each FICE mode (95% CI) 
FICE mode FICE 1 FICE 2 FICE 3 
Angioectasias (N=80) 0.89 (0.69-1.08) 0.43 (0.32-
0.54)* 
0.05 (0.04-0.07)* 
Ulcers/erosions (N=156) 0.45 (0.38-0.52)* 0.04 (0.03-
0.05)* 
0.04 (0.03-0.04)* 




Figure 3.3: Pooled proportions of images of angioectasias considered to show “improved” 
visualization under FICE: (a) FICE 1; (b) FICE 2; (c) FICE 3. 
 
Figure 3.4: Pooled proportions of images of ulcers/erosions considered to show “improved” 
visualization under FICE: (a) FICE 1; (b) FICE 2; (c) FICE 3. 
35 
 
3.3.3 Lesion detection 
A total of 10 studies73,83,85–92 measured improvement in detection of lesions. Of these, 3 
studies86,87,89 reported results as average numbers of lesions identified by multiple readers 
and could therefore not be included in analysis. Another 2 studies91,92 did not give results by 
types of lesions, instead using the Saurin score93; these could not be included for statistical 
analysis as the numbers of angioectasias and ulcers/erosions remained unknown. 
The remaining 5 studies were designed such that each video in each mode was viewed only 
once by one reader over the course of the study73,83,85,88,90. Therefore these were entered into 
the analysis, and ANOVA was carried out using the average number of lesions detected per 
video (Table 3.4). The F statistic for the difference in detection of angioectasias and 
ulcers/erosions in the three FICE modes compared to WLE had a P value >0.05 for both types 
of lesions, showing that the detection of these lesions did not differ significantly between 






Table 3.4 (a): Repeated measures ANOVA for detection of angioectasias 
 SS Df MS F 
Between 1.02 3 0.34 1.146 
Within 20.179 16 1.261  
-Error 3.559 12 0.297  
-Subjects 16.62 4 4.155  
Total 21.199 19   
F-Statistic Critical Value Result Conclusion 
1.146 3.4903 
Do not reject the null 
hypothesis. 
The compared groups do 
not differ significantly, 
F(3,12) = 1.146, P > 0.05. 
 
Table 3.4 (b): Repeated measures ANOVA for detection of ulcers/erosions 
 SS df MS F 
Between 3.467 3 1.156 1.723 
Within 41.093 16 2.568  
-Error 8.052 12 0.671  
-Subjects 33.041 4 8.26  
Total 44.56 19   
F-Statistic Critical Value Result Conclusion 
1.723 3.4903 
Do not reject the null 
hypothesis. 
The compared groups do 
not differ significantly, 
F(3,12) = 1.723, P > 0.05. 





3.3.4 Quality analysis of included studies 
The majority of the included studies were of high quality (Table 3.5). The main risk of bias 
identified was recall bias in studies where videos were viewed in more than one mode by the 
same reviewer. 
 
Table 3.5: Quality of studies and risk of bias as determined by QUADAS-2 assessment. 
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 3.4.1 Limitations of existing CE technology 
The technological limitations of CE mean that targeted focus on small-bowel lesions or areas 
of interest is not possible; any focus occurs only for the amount of time allowed by bowel 
movement and propulsion94. Furthermore, despite recent substantial improvements in 
image quality, particularly image resolution, the image pixellation of SBCE remains 
disappointingly low50,95, especially when compared with that of conventional high definition 
flexible endoscopes. This often leads to suboptimal lesion imaging and therefore potentially 
reduces the diagnostic yield of capsule endoscopy14,96. Software such as FICE, already 
established in conventional GI endoscopy, has been integrated into commercially available 
capsule endoscopy reviewing software (RAPID; Medtronic) in order to increase visualization 
and detection rate for small-bowel findings. However, clinical opinion and anecdotal 
evidence remain divided as to the usefulness of FICE and other chromoendoscopy software 
for capsule endoscopy review97. 
 
 3.4.2 Usefulness of FICE modes 
In this meta-analysis, all three FICE modes failed to show any statistically significant 
improvement in visualization of small-bowel pathology. Although with FICE setting 1 a pooled 
proportion of 89% of angioectasia images were considered “improved” (defined as improved 
visualization aiding lesion characterization and enhanced delineation of lesion surface and/or 
borders), compared with the WLE images, this was not statistically significant. For small-
bowel angioectasias viewed under FICE 2 and 3, and for mucosal ulcers/erosions viewed 
under all three FICE modes, less than 50% of the images were considered to be improved. In 
fact, for FICE modes 2 and 3, there was close to no improvement in ulcer/erosion visualization 
compared with WLE imaging. 
Therefore, FICE appears to perform well when there is significant color alteration of the 
lesion, as in angioectasias. This could be partially explained by the fact that pigmented fluids, 
such as blood and bile, allow the greatest contrast with small-bowel mucosa even under WLE. 
FICE further enhances this contrast, leading to subjective improvement in visualization, 
whereas it may not perform as well with nonpigmented lesions73,97. The most recent 
technical report from the American Society for Gastrointestinal Endoscopy (ASGE) states that 
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there is no evidence for an optimal FICE mode for tissue diagnosis and differentiation in 
conventional GI endoscopy51. 
Spada et al. defined the clinical usefulness of chromoendoscopy in terms of the following 
criteria: (i) improvement in lesion detection rate; (ii) improvement in lesion delineation; and 
(iii) ability to identify lesions which require treatment97. In fact, the number of lesions 
detected on full video reading may be a more accurate index of the clinical performance of 
FICE against WLE because of the unambiguous binary response of pathological finding 
detected or not. This approach is likely to be less subjective than assessment of delineation 
improvement as determined by human readers. The majority of pathological findings at 
capsule endoscopy consist of vascular lesions and mucosal defects. Polypoid or submucosal 
lesions, where software tools can enhance diagnostic accuracy62,98, are found less frequently. 
Therefore, in the video studies examining detection rate for small-bowel pathological 
findings, FICE did not produce any significant improvement in the detection of angioectasias 
or mucosal ulcers/erosions, compared to WLE video reading. Furthermore, all these studies 
relied on human vision and perception for detection of lesions. Psychological studies have 
shown that the colour red produces a stronger reaction in humans, therefore human readers 
may be more likely to pick up on red-coloured lesions (i.e., blood or vascular lesions) 
compared to the more muted green and brown tones in FICE modes 2 and 399–101. By 
extension, narrow band imaging (NBI) is based on the penetration properties of different 
wavelengths of light corresponding to the two light absorption peaks of haemoglobin, so as 
to increase the contrast and therefore visibility of vasculature51. The results of this meta-
analysis are similar overall to those achieved in studies on the use of virtual 
chromoendoscopy in conventional GI endoscopy: the value of virtual chromoendoscopy lies 
in aiding lesion visualization and therefore characterization, rather than in increasing 
detection51. Although all but one of the studies included in this meta-analysis involved 
experienced capsule endoscopy readers, a recent study found that using FICE and Blue mode 
also helped beginner capsule endoscopy readers to better characterize lesions53, suggesting 






 3.4.3 Comparison with other digital image enhancement techniques 
This review and meta-analysis has focused on FICE alone, although other virtual 
chromoendoscopy software is currently available such as Blue mode51 and Augmented Live-
body Image Color-Spectrum Enhancement (ALICE) (Intromedic, Seoul, South Korea)56. 
However, the existing body of data is small and too heterogeneous for more systematic 
analysis. Although in this meta-analysis FICE has not performed as well, there is some 
evidence for the usefulness of other forms of virtual chromoendoscopy, mainly Blue 
mode52,54,55,59. Current evidence suggests that Blue mode remains a more user-friendly form 
of virtual chromoendoscopy which can be applied with ease to full video readings. However, 
none of the existing studies have shown a meaningful increase in diagnostic yield with Blue 
mode. Interestingly, Aihara et al. presented a study using image-enhanced capsule 
endoscopy which increased the contrast between the surrounding mucosa and lesions such 
as vascular or inflammatory lesions or polyps. They reported that the effects of this contrast 
capsule are similar to those of NBI in conventional GI endoscopy102. The only study using 
ALICE, presented as an abstract, reported improved visibility of flat and depressed small-
bowel lesions56.  
 
 3.4.4 Limitations 
Limitations of this meta-analysis include, firstly, the heterogeneity of current published 
studies investigating the usefulness of FICE, as shown by the high I2 values. These studies 
varied considerably in terms of study design, selected population, images and videos for 
analysis, and models of capsule endoscope used with their subsequent effect on technical 
performance. For instance, differences in the LED specifications between the PillCam® 
versions could vary the image quality and interpretation between studies. The heterogeneity 
of study design meant that several could not be included in the meta-analysis, thus greatly 
limiting the sample size. None of the included studies reported whether the readers had been 
tested for color blindness; it is unclear whether this could influence intraobserver agreement. 
The majority of the studies included in this meta-analysis also did not specify the size or 






FICE 1 seems to perform better for pigmented lesions such as angioectasias, both in lesion 
delineation and detection. However, the evidence is equivocal as to whether FICE 2 and 3 aid 
CE reading. Overall, the use of the three FICE modes did not significantly improve detection 








Chapter 4 Systematic Review and meta-analysis: Suspected Blood Indicator 
The previous chapter examined the data for FICE as a method of digital image enhancement 
in order to improve image quality and diagnostic ability. As previously discussed, the other 
major type of software available to aid capsule reading is that of image or frame selection 
software. This chapter aims to investigate the clinical effectiveness of suspected blood 
indicator (SBI) software in selecting video frames which could potentially represent GI 
bleeding and flagging these frames or video segments up for review, as it represents the main 
type of image selection software in CE reading. 
 
4.1 Introduction: SBI 
The SBI is an image selection feature developed by Medtronic® as part of its RAPID® CE 
reading software. It tags video frames with red pixels which could represent possible areas 
of haemorrhage in the GI tract. Similar software is available using the OMOM VUE platform 
and also for the Olympus Endocapsule®. However, the clinical usefulness of SBI is debatable; 
although the few published studies suggest it has a sensitivity of up to 80% in active GI 
bleeding, it appears to have a much lower sensitivity (around 25%) for lesions with bleeding 
potential but not bleeding at time of imaging. Therefore, the overall sensitivity and specificity 
is estimated at 40-60%103,104. Furthermore, there is very limited data on the use of SBI in CE 






 4.2.1 Search strategy 
A comprehensive literature search was conducted using the databases PubMed and Embase 
on the 20th of August 2016, capturing articles from January 2000 until the search date. The 
search terms used were “capsule endoscopy” (both as keyword and MeSH term) AND 
“suspected blood indicator” (as keyword as no MeSH term was available). The search was 
performed with no limitations. 
Initial screening of publications was carried out via title and keywords. Following 
identification of potentially relevant articles, full text selection was carried out according to 
the inclusion and exclusion criteria detailed below. References were manually cross-checked 
to ensure no publications had been missed. A flowchart detailing study selection is shown in 
Figure 5.1. 
The inclusion criteria were: observational and case-control studies of the use of SBI in CE 
cases, encompassing all areas of the GI tract, both prospective and retrospective, articles 
published in English. Exclusion criteria were: systematic reviews and/or meta-analyses, 
editorials, opinion papers, reviews, studies where SBI was not used in actual patients. 
Data extraction and quality control were performed independently by myself and a second 
author. A third reviewer, expert in the content material, was involved if any conflict occurred. 
Where additional data were required, attempts were made to contact the primary (first 
and/or senior) or corresponding authors of the relevant manuscript(s) via electronic mail. 




























Literature search using PubMed and Embase: 
 “capsule endoscopy” (keyword and MeSH term) 
AND 
“suspected blood indicator” (keyword) 
Full-text review: 20 studies 
Exclusions: 5 
Abstracts also published as full papers (n=3) 
Simulator model used (n=2) 
15 relevant studies identified 
References and review articles cross-checked 
Addition of 1 study: Signorelli et al, 2005 
16 studies included in analysis 
Exclusions from meta-analysis: 7 
Only positive SBI results reported (n=3) 
Sample size inadequate (n=1) 
Insufficient information for statistical analysis (n=3) 
9 studies in meta-analysis 
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4.2.2 Outcome measures 
The diagnostic accuracy (sensitivity, specificity, diagnostic odds ratio (DOR)) of SBI software 
for the diagnosis of GI bleeding was evaluated. For each study, the numbers of true positive, 
true negative, false positive and false negative results were listed. CE findings reported by 
human reviewers were considered the reference standard. 
 
 4.2.3 Statistical analysis 
The bivariate model was used for data summary, following which parameter estimates from 
the model were used to obtain summary receiver operating characteristic curves (SROC) 
depicting test accuracy via the relationship between sensitivity and specificity105. The closer 
the curve approaches the 45-degree diagonal of the SROC space, the less accurate the test. 
The area under the curve (AUC) represents test accuracy, ranging from 0.5 (poor accuracy) 
to 1.0 (excellent accuracy). Similarly, index Q* corresponds to the uppermost point on the 
SROC where sensitivity equals specificity; the range of values is the same as that of the AUC. 
Only direct test comparisons were performed. 
I2 was used to estimate the heterogeneity of individual studies contributing to the pooled 
estimate76. Due to high statistical heterogeneity overall, the DerSimonian-Laird random 
effects model was applied. The effects of heterogeneity between studies were assessed using 
sensitivity analyses of the following subgroups: studies investigating small bowel bleeding 
only, studies investigating active bleeding only, studies where results were reported using 
full CE examinations rather than individual lesions and the exclusion of studies at high risk of 
bias as defined by QUADAS-2. 
The QUADAS-2 scale was used to evaluate quality of the included studies78. The “index test” 
was SBI and human CE readers taken to be the “reference standard”. Item 7 was considered 
“not applicable” as any time difference between analysis by readers and with SBI would not 
affect results. Analyses were conducted using Meta-DiSc 1.4 software106 (Ramon y Cajal 





4.3 Results and meta-analysis 
 4.3.1 Search results and included study characteristics 
The PubMed search yielded 10 results with 6 relevant articles identified. Embase search 
yielded 31 results, included all 6 articles identified from PubMed search. In total 20 articles 
were tagged as relevant. 
Three abstracts60,107,108 were excluded as they were later published as full papers58,109,110 
which were included in this analysis. Another 2 articles111,112 were excluded as they used a 
simulator model and not actual patients. 
One more study was identified through manual reference review104; this was likely to have 
been missed in the initial search due to title wording. Therefore, 16 studies were eventually 
identified as relevant for further review. 
The included studies are summarised in Table 4.1. The 16 studies included58,103,118–
123,104,109,110,113–117 had been published between 2003 and 2016. Countries of origin were: USA 
(n=6)58,103,110,113,120,121, and 1 each from Australia123, Canada114, France122, Germany109, India118, 
Italy104, South Korea116, Portugal119, Spain115, UK117. Nine were abstracts113–121 and 7 had been 
published as full papers58,103,104,109,110,122,123. Only one study was multicentre122. Seven were 

















































































USA Single Prosp 72 72 NS Given, NS Post-
transfusion 
pts only 




Full video 16 1 55 0 
Liangpunsakul, 
2003103 





Experienced Both Small 
bowel & 
stomach 
Per lesion 28 3 17 81 
Zanati, 2004114 
(Abstract) 
Canada Single Retro 42 42 M2A® NS NS NS NS Both Small 
bowel 
Per lesion 18 41 NS NS 
D’Halluin, 
2005122 
France Multi Prosp 156 156 M2A® RAPID, NS OGIB NS >50 CEs Both Small 
bowel 
Full video 28 26 68 34 
Kitiyakara, 
2005123 
Australia Single Prosp 9 9 M2A® NS OGIB NS NS Both Non-
small 
bowel 
Full video 6 0 0 1 
Signorelli, 
2005104 
Italy Single Retro 100 95 M2A® RAPID, NS All* 4 All >100 CEs Both Small 
bowel 




Spain Single Prosp 57 57 M2A® NS 
+ QV 
All 2 Experienced NS Small 
bowel 
Full video These values were not given; 40 CE videos had 






Single Retro 96 96 NS RAPID, NS Overt OGIB 2 Expert Both NS NS which 














USA Single Retro 287 287 M2A® RAPID, NS All 5 initial; 
findings 
confirmed 
by 1 more 
reader 
>50 CEs Both Small 
bowel 
Full video 44 139 70 34 
Beejay, 2009117 
(Abstract) 
UK Single Prosp 347 347 NS NS All NS NS Both Small 
bowel 
Per lesion 10613 7076 NS NS 
Reddy, 2010118 
(Abstract) 




OGIB 1 NS Both NS NS These values were not calculable given information 
in abstract; accuracy parameters were only reported 
as percentages. 









































Full video 42 137 20 0 
Barbosa, 2015119 
(Abstract) 
Portugal Single Retro 300 300 NS NS 
+ QV 
OGIB 2 NS Both Small 
bowel 
Full video 37 0 212 51 
Han, 2015120 
(Abstract) 
USA Single Retro 115 115 NS RAPID 
Reader 
6.0 




Full video 115 0 NS NS 
Han, 2016121 
(Abstract) 
USA Single Prosp 100 100 NS RAPID 
Reader 
6.0 
OGIB NS NS Active 
bleeding 
NS Full video 18 0 82 0 
 
Abbreviations: CE capsule endoscopy; FN false negative; FP false positive; pts patients; NS not specified; OGIB obscure gastrointestinal bleeding; prosp prospective; QV QuickView®; retro retrospective; SBI suspected blood 
indicator; TN true negative; TP true positive; UK United Kingdom; USA United States of America 
* “All” indications for CE refers to the inclusion of all conventional indications including OGIB, suspected inflammatory bowel disease, suspected neoplasia, coeliac disease, polyposis syndromes etc. 
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In total, this analysis comprised 2040 patients who underwent 2049 CE examinations. The 
most frequently used capsule model was M2A® (Medtronic, USA) (7 studies, 670 
examinations)103,104,110,114,115,122,123; 2 studies used PillCam®SB/SB2 (233 CE 
examinations)109,118. In 7 studies58,113,116,117,119–121 the model of capsule was not specified. The 
SBI software used was RAPID® version 6 (4 studies, 530 CE examinations)58,109,120,121 and 
RAPID® version 4 (1 study, 34 CE examinations)118. Eleven studies did not specify the software 
used103,104,123,110,113–117,119,122. 
In 5 studies with 985 CE examinations104,109,110,115,117, the indications for CE were mixed. They 
included all CE cases done at the various centres e.g. referrals for OGIB, suspected 
inflammatory bowel disease, and suspected small bowel neoplasia. Nine studies (998 
examinations)58,113,116,118–123 included only CE examinations done for OGIB. Out of these, 2/9 
studies (211 examinations)116,120 included only patients with overt OGIB. One of these nine 
studies (72 examinations)113 examined only post-transfusion patients. Two studies did not 
specify the indications for CE103,114. 
The number of CE readers ranged from 1-6 (not specified in 7 studies). In 8/9 studies, the 
readers were “experienced” to “expert”58,103,104,109,110,115,116,122 although the level of CE reading 
experience was quantified in numbers in only 4 studies104,109,110,122. In one study58, the 
performance of SBI was compared to novice CE readers with only 25 CEs’ experience. 
Interobserver agreement was reported in only 3 studies58,104,110; all 3 reported excellent 
agreement. 
In 11 studies58,104,123,109,110,113,115,119–122, results were considered true positives if there was at 
least one lesion in each video flagged by both the SBI and the readers. Therefore not all 
lesions in each CE examination needed to be picked up by the SBI in order for the examination 
to be considered true positive. Conversely, 3 studies103,114,117 reported results as the 
agreement between SBI and readers for each individual lesion. The method of determining 
SBI accuracy was unclear in 2 studies116,118. 
Three studies used both SBI and QuickView®58,115,119. Another 3 studies reported only positive 
SBI results114,117,120. 
In 5 studies (602 examinations)58,109,113,120,121, only active bleeding was considered a positive 
finding. Ten studies (1390 examinations)103,104,110,114,116–119,122,123 included both active bleeding 
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and potentially bleeding lesions. One study115 did not specify what was counted as a positive 
finding. 
Ten studies (1671 examinations)58,104,109,110,113–115,117,119,122 reported small bowel findings only. 
Two studies reported any findings in the entire gastrointestinal tract103,120. One study123 
reported only non-small bowel findings. In 3 studies, this information was not 
specified116,118,121. 
 
4.3.2 Quality analysis of included studies 
Overall, 4 studies103,104,109,110 were considered good quality (i.e. at low risk of bias, based on 
QUADAS-2 analysis), 7 were moderate in quality58,114,115,117–119,122 and 5 were at high risk of 
bias113,116,120,121,123. There were many significant sources of bias identified. The largest 
potential source of bias was in patient selection, due to those studies which included only 
patients with OGIB and specifically overt OGIB; this could falsely increase diagnostic yield. 
Many studies were also unclear about whether the readers were aware of SBI results when 






Table 4.2: QUADAS-2 results for the included studies. Item 7 of QUADAS-2 is not applicable 

























































































































































































































Gross, 2003113        
Liangpunsakul, 2003103        
Zanati, 2004114        
D’Halluin, 2005122        
Kitiyakara, 2005123        
Signorelli, 2005104        
Ponferrada Diaz, 2006115        
Jeen, 2007116        
Buscaglia, 2008108        
Beejay, 2009117        
Reddy, 2010118        
Stein, 201458        
Tal, 2014109        
Barbosa, 2015119        
Han, 2015120        








Seven of the 16 studies could not be meta-analysed. The reasons are as follows: Three studies 
(504 CE examinations)114,117,120 reported positive SBI results only with no corresponding group 
of negative SBI cases, one study had only 7 patients123 and another three studies (with 187 
CE examinations)115,116,118 did not provide a sufficient breakdown of results and no contact 
information was available. 
The CE examinations in Stein et al58 were counted twice as the performance of SBI was 
compared to two separate readers. This was in contrast to all other studies where SBI was 
compared to a single reference standard, i.e. the consensus of readers, or this information 
was not specified. 










Table 4.3: Summary of meta-analysis results 
Subgroup No. of 
studies 






DOR (95% CI) 














Only moderate to 
good quality 
studies 














Studies where any 
match between SBI 
















Abbreviations: CE capsule endoscopy, CI confidence interval, DOR diagnostic odds ratio 
*Note that the CE examinations from Stein et al are counted twice as the performance of SBI was compared to 2 





The overall sensitivity of SBI for any bleeding or potentially bleeding lesions was 0.553 (95%CI 
0.510-0.596), Figure 4.2(a). The specificity was 0.578 (95%CI 0.547-0.608), Figure 4.2(b), and 
DOR 12.354 (95%CI 3.297-46.297). The studies displayed high heterogeneity with I2 values 
above 80%. The SROC for the overall sensitivity and specificity of SBI is shown in Figure 4.2(c); 
the AUC (0.878) and Q* (0.809) both show good accuracy. 
However, the sensitivity of SBI for active bleeding only was 0.988 (95%CI 0.956-0.999), Figure 
4.3(a). The specificity of SBI for active bleeding was 0.646 (95% 0.610-0.680), Figure 4.3(b), 
DOR 229.89 (95%CI 20.748-2547.3). The SROC for SBI in active bleeding shows excellent 
accuracy in this scenario with AUC 0.993 and Q* 0.966, Figure 4.3(c). 
When only moderate to good quality studies (based on QUADAS-2 analysis) were included, 
the sensitivity of SBI was 0.523 (95%CI 0.478-0.567), Figure 4.4(a), specificity 0.515 (95%CI 
0.482-0.548), Figure 4.4(b), and DOR 4.327 (95%CI 1.442-12.989). The SROC for SBI in the 
moderate to good quality studies, Figure 4.4(c), shows a relatively poor performance of SBI 
with low AUC (0.755) and Q* (0.697). 
 
4.3.4 Sensitivity analyses 
The sensitivity of SBI for small bowel findings was similar at 0.613 (95%CI 0.564-0.660), 
specificity 0.535 (95%CI 0.503-0.568) and DOR 9.650 (95%CI 2.404-38.738). 
In the studies where a single match between SBI and reader per examination/video was 
considered a true positive, results remained similar with sensitivity 0.629 (95%CI 0.581-
0.675) and specificity 0.573 (95%CI 0.542-0.603). The DOR for this group was 17.139 (95%CI 
3.855-76.193). 
In the studies using the first version of PillCam® (M2A®), the sensitivity was poorer at 0.403 






Figure 4.2: Pooled measures of diagnostic accuracy of SBI for all lesions with bleeding 
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Figure 4.3: Pooled measures of diagnostic accuracy of SBI for active bleeding. (a) sensitivity; 





























Figure 4.4: Pooled measures of diagnostic accuracy of SBI, taking into account only studies 





























 4.4.1 Application of SBI in current clinical practice 
Overall, the SBI software displayed poor to moderate sensitivity (55.3%) and specificity 
(57.8%) in detecting small bowel pathology with bleeding potential. However, SBI showed 
high sensitivity (98.8%) for active bleeding alone although its specificity remained low at 
64.6% even in this clinical scenario. As mentioned previously, there have been studies 
investigating the effects of using CE earlier in the clinical assessment of suspected GI 
bleeding11,124,125. Although real-time viewers are now integrated into the majority of CE 
hardware, the images obtained still require reader interpretation126. Therefore, the use of 
artificial intelligence in CE reading is an attractive concept which has been gaining ground 
steadily61,62,127. Indeed, the sensitivity of SBI for active bleeding could further support the use 
of CE in the acute setting. For example, studies have shown that emergency physicians can 
perform CE reading for acute GI bleeding with minimal prior training128,129; the use of SBI can 
speed up this process. In this context, a robust SBI tool in conjunction with automated 
reading will allow for better clinical outcomes as highly-qualified clinical staff can be diverted 
to more skill-demanding tasks such as therapy of bleeding130. 
Furthermore, this meta-analysis highlights current technological limitations of using image-
processing methods to aid CE reading. The SBI tool processes images based on wavelength 
and colour contrast. Interestingly, Park et al112 conducted an experiment using SBI to detect 
simulated lesions against various coloured backgrounds. The SBI performed better with red 
lesions on a pale background, i.e. in frames with higher colour contrast. Similar results have 
been demonstrated in studies of other image enhancement software e.g. FICE or blue 
mode55,131. One plausible explanation for the overall moderate performance of the SBI 
software is that not all bleeding lesions are bright red or contrast strongly with bowel 
mucosa. Moreover, the size of a lesion and hence the number of red pixels in a frame does 
not always correlate with bleeding potential97. A combination of CE reading software aids 
could be a viable method for improving detection and shortening reading times, e.g. a 






 4.4.2 Limitations 
Limitations of this review and meta-analysis include the marked heterogeneity of the 
included studies. Most studies reported accuracy parameters using the number of studies 
with any agreement between SBI and readers, rather than the agreement per lesion/area 
identified by the SBI. This is potentially misleading as the criteria for “true positives” in these 
cases was for a video to have one area flagged by SBI which was also determined by readers 
to have blood/a lesion. Therefore these videos could still contain other missed lesions. There 
was also limited information on review conditions used by the readers, such as speed of 
review and version of software. Most of the studies which did report capsule model used the 
M2A® capsule which is now superseded by newer versions; additional sensitivity analysis 
showed lower sensitivity in the studies which used M2A®. The analysis was further hampered 
by large amounts of missing information as several of the studies were abstracts. Finally, it 
was often unclear how a positive SBI finding was defined. Some studies defined a positive SBI 
as a specified number of flagged frames but others did not include this information. 
 
4.5 Conclusion 
The meta-analysis results show that the current SBI tool has limited validity in CE reading. 
However in the clinical context of active GI bleeding, it has good sensitivity, therefore 







Chapter 5 Systematic Review and Meta-analysis: use of laxative bowel preparation in 
CE 
In this third meta-analysis, I move on to clinical methods of image enhancement in CE. As 
previously discussed, the effectiveness of simethicone in reducing bubbles and therefore 
improving visualisation of the bowel lumen has already been established. This chapter 
therefore aims to investigate the effectiveness and clinical utility of laxative bowel 
preparation for CE. 
 
5.1 Introduction: Role of laxatives in CE 
The optimal pre-CE bowel preparation is a much-debated topic amongst CE users worldwide. 
Several regimes have been proposed with different laxatives, dosages and administration 
timing. Those in favor argue that laxatives improve image quality and SB mucosal 
visualization, therefore potentially increasing diagnostic yield65,66. Conversely, those 
advocating a clear liquid diet and pre-procedural overnight fast believe that this achieves 
adequate visualization with superior patient comfort and acceptability67. Despite several 
clinical studies and a few meta-analyses68–71,132, the role of pre-procedural bowel purge 
remains controversial as no official societal guidelines exist133. 
Since the previous meta-analyses have been published, several more articles with 
contradictory messages have entered the literature. In this analysis I aimed to explore the 
effects of bowel preparation in SBCE by analyzing several parameters and outcomes of SBCE 
examination as per previous meta-analyses68–71. The primary outcome analysed is diagnostic 
yield for any findings and also clinically significant findings; secondary outcomes are SB 






5.2.1 Study selection 
A comprehensive literature search of PubMed, Medline and Embase was conducted, through 
to September 2016, in order to identify relevant articles. The search terms used were 
“capsule endoscopy” (as keyword and MeSH term) AND [“preparation”, “bowel 
preparation”, “purgatives”, “laxatives”, “(preparation OR purge)”, “cleansing” OR 
“prokinetics”], capturing studies from January 2000 to September 2016. Potentially relevant 
studies were initially identified by title and abstract; full texts were retrieved for detailed 
review and inclusion/exclusion criteria were applied. Further manual reference searches 
were conducted from the reference lists of review articles, editorials and previous meta-
analyses, as well as those of all retrieved papers. Data were extracted independently by 
myself and a second reviewer. Disagreements and discrepancies were settled by a consensus 
opinion of three senior reviewers, experts in the subject matter, who were consulted when 
necessary. 
Articles were included based on the criteria: (i) Published as full papers only, (ii) In English, 
(iii) Observational and interventional studies, (iv) On the use of laxatives in SBCE (whether 
compared with no laxatives or not), (v) Measuring the parameters of diagnostic yield for any 
findings and/or significant findings, SBVQ, CR, (vi) Adult patients only. 
Studies not meeting these criteria were excluded. Additional exclusion criteria were: (i) Small 
sample size (n<10), (ii) Conference abstracts, letters, editorials, reviews, and meta-analyses, 
(iii) Insufficient data for meta-analysis and/or duplicate publications. 









5.2.2 Outcome measures 
The primary outcome was diagnostic yield (abbreviated for this chapter as “DY”): any 
findings seen on SBCE including those “possibly” the cause of the patient’s presentation, with 
a further subgroup of “definitely” significant findings, as defined by authors of the original 
articles. 
Secondary outcomes were: 
Small bowel visualization quality (SBVQ): as defined by authors of included studies; if not, 
only “good” and “excellent” ratings were considered adequate. Studies which reported 
results as an average of visual rating, scores, without breakdown of results into 
adequate/inadequate numbers, were excluded from meta-analysis. When authors reported 
SBVQ per SB segment (i.e. proximal, middle, distal) we considered SBVQ adequate only when 
rated “good/excellent” in all segments. 
Completion rate (CR): number of SBCE examinations where the caecum was visualised, a 
consistent definition across all articles. 
 
5.2.3 Statistical analysis 
From the data extracted, pooled odds ratios (ORs) and proportions, with 95%CIs, were 
obtained for the outcomes (i) DY for all findings and significant findings; (ii) SBVQ and (iii) CR. 
The fixed effects model was used unless significant heterogeneity was present, where the 
random effects model was applied. For the outcome SBVQ, the number needed to treat 
(NNT) was estimated as the inverse of pooled risk differences134,135. Meta-analysis was 
conducted using the “meta” and “metafor” packages136,137 in R statistical software version 
3.3.1 (R Foundation for Statistical Computing, Vienna, Austria). 
In the presence of significant statistical heterogeneity, sensitivity analyses were conducted 
to evaluate the consistency of results. Outliers were identified and meta-analyses repeated 
without them to determine whether their exclusion significantly altered the magnitude or 
heterogeneity of the summary estimate. Further subgroup analyses were conducted to 
determine the potential effects of different study designs and populations: type of laxatives 
used, use of simethicone and/or prokinetics, timing of administration of laxatives, large 
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studies only (≥30 SBCEs in both laxative and control groups), high quality studies only as 
defined below, retrospective vs prospective study design (which also corresponded to 
cohort-based studies vs randomised controlled trials respectively). 
Likelihood of publication bias was assessed with the construction of funnel plots, by plotting 
log ORs against precision (1/SE) of individual studies. Funnel plot symmetry was assessed 
using Egger’s regression asymmetry test, and significant asymmetry was deemed present if 
P<0.05138. 
 
5.2.4 Quality assessment of included studies 
Potential bias of the included studies was evaluated using the scoring system proposed by 
Rokkas et al71, felt to be most specific to the topic of this meta-analysis. The items scored 
are as follows: 
(1) Type of study: prospective (1 point) or retrospective/cohort study (0 points) 
(2) Number of examiners: ≥2 (1 point) or only 1 (0 points) 
(3) Blinding of examiners to preparation: yes (1 point) or no (0 points) 
(4) Number of grades for overall bowel cleansing: ≥3 (1 point) or ≤2 (0 points) 
(5) Whether the entire small bowel was evaluated: yes (1 point) or no (0 points) 
Studies scoring 4/5 and above were considered to be high quality, studies scoring 2/5 and 





5.3 Results and meta-analysis 
5.3.1 Study selection and included study characteristics 
The initial search yielded 269 citations. Of those, 260 articles were found in PubMed; a 
subsequent Embase search found an additional 9 articles. These results were corroborated 
using Medline. On title and abstract review alone, 188 articles were excluded as non-
relevant. Therefore, 81 articles proceeded to full text review. The detailed flow chart 
describing the process is presented in Figure 5.1. 
The 40 studies that were eligible for final analysis were published from 2004-2016139,140,149–
158,141,159–168,142,169–178,143–148. Out of these, 32 studies compared the use of laxatives against a 
control group who did not receive laxatives139,140,149–152,155–159,161,141,162–168,171,174,175,142,176,178,143–
148; 8 studies examined only patients given laxatives (i.e. comparing one type of laxatives 
against another/ one regimen against another)153,154,160,169,170,172,173,177. Detailed study 
characteristics are shown in Table 5.1. 
In total, 4380 patients received laxatives, while 2185 patients did not receive laxatives prior 
to SBCE. Polyethylene glycol (PEG) was used in 32 studies (3402 patients)139,141,154,156–160,162–
165,142,167–176,143,177,178,144,146–148,151,153; sodium phosphate (NaP) in 11 studies (553 
patients)150,157,160164,171139,140,144–146,149; 3 studies (134 patients) used Magnesium Citrate 
(MgC)152,155,166; another 3 studies (118 patients) used sodium picosulphate with MgC173,175,178. 





Figure 5.1: Study selection for studies examining the use of laxative bowel preparation in CE 
 
 
Database search of  
PubMed, Embase and Medline: 
269 potentially relevant articles 
Initial screening by title and abstract 188 articles excluded 
Full-text review: 81 articles 
Exclusions on full text review:  41 articles 
 Letters, editorials, reviews and 
previous meta-analyses (n=18) 
 Conference abstracts (n=16) 
 Simethicone or prokinetic only (n=4) 
 Paediatric population (n=1) 
 Inadequate sample size (n=1) 
 Validation of cleansing score (n=1) 
Reference search:  
No further articles identified 
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Israel Single Retro M2A® - 2, blinded PEG 
NaP 
 None 22 
(PEG: 9, 
NaP: 13) 





Israel Single Retro Ns - 2, blinded NaP None 22 10 8h fast % time - Moderate 
Viazis, 
2004 141 
Greece Single Prosp M2A® Randomised 3, blinded PEG None 40 40 Overnight 
fast 
% of time 















Switzerland Multi Prosp M2A® By centre 3, blinded PEG None 33 29 12h fast Amount of 






Israel Single Retro M2A® - 1, blinded PEG 
NaP 







Multi Retro Ns By centre 1, blinded NaP None 23 23 Overnight 
fast 
% time Any lesions High 
Kalantzis, 
2007 146 
Greece Multi Retro PillCam® 
SB 


















































France Multi Prosp PillCam® 
SB 
Randomised 2, blinded NaP None 63 64 8h fast Amount of 
debris and % 
mucosa 
visibility 
Saurin Score Low 
Wei, 2008 
151 
China Single Prosp M2A® Randomised 1, blinded PEG Simethicone 
(some pts) 
60 30 12h fast + 
1L clear 
fluids 
% of time 





Japan Single Retro M2A®, 
PillCam® 
SB 
- 1 MgC Simethicone 
(some pts) 




Any lesions High 
Fang, 2009 
153 
China Single Prosp M2A® Randomised Ns PEG Simethicone 
(some pts) 
64 - - % bubbles - High 
Kantianis, 
2009 154 
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Japan Single Prosp PillCam® 
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Randomised 4, blinded PEG Dimethylpolysilox
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20 20 Overnight 
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Italy Single Prosp PillCam® 
SB 
Randomised 3, blinded PEG None 30 30 Overnight 
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u, 2010 160 
Greece Multi Prosp PillCam® 
SB 


























of % mucosa 
visibility 
Any findings Low 
Hosono, 
2011 162 
Japan Single Prosp PillCam® 
SB/ SB2 








South Korea Single Prosp Ns Randomised Ns PEG None 45 23 12h fast % of time 
















92 8h fast + 
4L clear 
fluids 
Rating - Moderate 
Ito, 2012 
165 
Japan Single Prosp PillCam® 
SB 





Japan Single Prosp PillCam® 
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Any findings Moderate 
Niv, 2013 
167 
Israel Multi Prosp PillCam® 
SB2 
Randomised 1, blinded PEG None 50 148 Overnight 
fast (45), 












Portugal Single Prosp PillCam® 
SB2 
Randomised 2, blinded PEG Simethicone 
(some pts) 





























USA Single Prosp PillCam® 
SB 
Randomised 1, blinded PEG Simethicone 34 - - Rating, 
multiple 
parameters 
Saurin Score Moderate 
Lim, 2015 
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el, 2015 172 
Greece Single Prosp PillCam® 
SB 
Ns Ns PEG Simethicone 
(some pts) 
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Abbreviations: DY diagnostic yield, LS Lewis Score, MgC magnesium citrate, NaP sodium phosphate, ns not specified, PEG polyethylene glycol, pts patients, SBVQ small bowel visualisation quality 
*Study design: Prosp. prospective, Retro. retrospective 
**SBVQ: “rating” refers to subjective grading systems based on “excellent”, “good”, “fair” and “poor” categories or similar. “% mucosa visibility” refers to systems based on the amount of small bowel mucosa 




 5.3.2 Quality assessment of included studies 
This is detailed in Table 5.2. 
Table 5.2: Quality assessment of included studies 
Authors, Year 
(ref) 
Type of study: 
Prospective (1 pt) 
Retrospective 
/Cohort (0 pt) 
No. of CE 
readers: 
≥2 (1 pt) 
1 (0 pt) 
Blinding of 
readers: 
Yes (1 pt) 
No (0 pt) 
No. of grades for 
overall bowel 
cleansing: 
≥3 (1 pt) 
≤2 (0 pt) 
Evaluation of entire 
SB in all CEs: 
Yes (1 pt) 








0 1 1 0 0 2 High 
Niv, 2004 140 0 1 1 1 0 3 Moderate 
Viazis, 2004 141 1 1 1 0 0 3 Moderate 
Ben-Soussan, 
2005 142 
0 0 1 1 0 2 High 
Dai, 2005 143 1 1 1 1 0 4 Low 
Fireman, 2005 
144 
0 0 1 1 0 2 High 
Niv, 2005 145 0 0 1 1 0 2 High 
Kalantzis, 2007 
146 
0 1 1 1 0 3 Moderate 
van Tuyl, 2007 
147 
1 1 1 0 0 3 Moderate 
Endo, 2008 148 1 1 1 1 0 4 Low 
Franke, 2008 149 1 1 1 1 1 5 Low 
Lapalus, 2008 
150 
1 1 1 1 0 4 Low 
Wei, 2008 151 1 0 1 1 1 4 Low 
Esaki, 2009 152 0 0 0 1 0 1 High 
Fang, 2009 153 1 0 0 1 0 2 High 
Kantianis, 2009 
154 
1 0 1 1 0 3 Moderate 
Postgate, 2009 
155 
1 0 1 1 0 3 Moderate 
Rey, 2009 156 1 0 0 1 1 3 Moderate 
Wi, 2009 157 1 1 1 0 0 3 Moderate 
Nouda, 2010 158 1 1 1 1 0 4 Low 
Spada, 2010 159 1 1 1 1 0 4 Low 
Triantafyllou, 
2010 160 
1 1 1 1 0 4 Low 
Chen, 2011 161 1 1 1 1 1 5 Low 
Hosono, 2011 
162 
1 1 1 1 0 4 Low 
Park, 2011 163 1 0 0 1 0 2 High 
Pons Beltran, 
2011 164 
1 0 1 1 0 3 Moderate 
Ito, 2012 165 1 0 1 1 0 3 Moderate 
Ninomiya, 2012 
166 
1 0 1 1 0 3 Moderate 
Niv, 2013 167 1 1 1 1 0 4 Low 
Rosa, 2013 168 1 1 1 1 0 4 Low 
Kim, 2014 169 1 0 1 1 0 3 Moderate 
Black, 2015 170 1 0 1 1 0 3 Moderate 
Lim, 2015 171 0 1 0 1 0 2 High 
Papamichael, 
2015 172 
1 1 1 1 0 4 Low 
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Adler, 2016 173 1 0 1 1 1 4 Low 
Catalano, 2016 
174 
0 0 1 1 0 2 High 
Hookey, 2016 
175 
1 1 1 1 0 4 Low 
Klein, 2016 176 0 0 0 0 0 0 High 
Magalhaes-
Costa, 2016 177 
1 1 1 1 1 5 Low 
Rayner-Hartley, 
2016 178 
0 1 1 1 1 4 Low 






A summary of meta-analysis results is shown in Table 5.3(a) (pooled proportions) and Table 
5.3(b) (pooled ORs). 
Table 5.3: Summary of meta-analysis results 
















DY for all SB findings 
ALL LAXATIVES 26 1816 58 52-64 80.9 <0.0001 
No laxatives 20 1235 52 46-58 70.2 <0.0001 
PEG 20 1294 58 52-63 72.1 <0.0001 
PEG given before 
SBCE only 
17 1218 56 50-62 69.7 <0.0001 
NaP 6 213 68 49-82 80.6 <0.0001 
NaP given before 
SBCE only 
5 200 74 59-85 74.4 0.004 
DY for significant SB findings 
ALL LAXATIVES 19 1584 45 39-52 82.7 <0.0001 
No laxatives 13 1033 42 33-51 84.6 <0.0001 
PEG 16 1189 45 38-52 79.9 <0.0001 
PEG given before 
SBCE only 
15 1162 43 36-50 77.7 <0.0001 
NaP 3 155 60 43-75 75.6 0.02 
NaP given before 
SBCE only 
3 155 60 43-75 75.6 0.02 
SBVQ (proportion of studies where adequate visualisation was achieved) 
ALL LAXATIVES 16 2979 68 59-76 91.5 <0.0001 
No laxatives 12 1318 53 37-68 93.7 <0.0001 
PEG 14 2557 64 52-74 92.3 <0.0001 
PEG given before 
SBCE only 
11 909 64 48-78 92.8 <0.0001 
NaP 6 404 76 66-84 72.4 0.0003 
NaP given before 
SBCE only 
5 233 72 65-77 55.3 0.06 
CR 
ALL LAXATIVES 30 2159 84 81-87 66.6 <0.0001 
No laxatives 25 1519 80 76-83 56.3 0.0003 
PEG 26 1610 84 78-88 73.5 <0.0001 
PEG given before 
SBCE only 
20 1452 85 81-88 69.6 <0.0001 
NaP 8 356 78 73-82 0 0.82 
NaP given before 
SBCE only 
7 343 78 73-82 0 0.90 
Abbreviations: CI confidence interval, CR completion rate, DY diagnostic yield, NaP sodium phosphate, PEG 
polyethylene glycol, SB small bowel, SBCE small bowel capsule endoscopy, SBVQ small bowel visualisation quality 
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DY for all SB findings 
ALL LAXATIVES 19 1139 1188 1.11 0.85-1.44 39.1 0.0418 
PEG 13 808 956 0.90 0.74-1.10 27.6 0.1666 
NaP 5 166 181 1.40 0.88-2.22 0 0.4882 
Other laxatives 4 165 162 1.30 0.83-2.05 52.7 0.0959 
Laxatives given 
before SBCE only 
17 1077 1108 1.12 0.85-1.48 41.3 0.0389 
With simethicone 5 201 203 1.25 0.83-1.89 46.3 0.1142 
No simethicone 15 938 1005 0.95 0.78-1.14 35.1 0.0879 
Low risk of bias 
only 
7 317 327 0.95 0.68-1.32 38.3 0.1366 
Large studies 
only 
10 845 975 1.11 0.76-1.63 63.4 0.0035 
DY for significant SB findings 
ALL LAXATIVES 12 904 987 1.10 0.76-1.60 60.2 0.0037 
PEG 10 720 849 0.90 0.73-1.11 59.7 0.0079 
NaP Insufficient data for meta-analysis 
Other laxatives 3 184 182 1.51 0.83-2.96 52.0 0.1247 
Laxatives given 
before SBCE only 
Insufficient data for meta-analysis 
With simethicone 3 125 124 0.78 0.46-1.32 0 0.6368 
No simethicone 10 779 883 1.19 0.76-1.87 66.0 0.0017 
Low risk of bias 
only 
5 207 260 0.83 0.42-1.63 58.0 0.0494 
Large studies 
only 
8 769 896 1.11 0.68-1.80 73.1 0.0005 
SBVQ (studies where adequate visualisation was achieved) 
ALL LAXATIVES 13 2767 1354 1.60 1.08-2.36 64.9 0.0006 
PEG 11 2363 1321 1.44 1.01-2.06 53.4 0.0181 
NaP 6 404 657 2.10 1.03-4.29 77.1 0.0006 
Other laxatives Insufficient data for meta-analysis 
Laxatives given 
before SBCE only 
10 948 838 1.83 1.07-3.12 71.8 0.0002 
With simethicone 3 84 82 2.31 0.53-10.1 68.0 0.0439 
No simethicone 12 2683 1318 1.53 1.04-2.25 62.8 0.0018 
Low risk of bias 
only 
Insufficient data for meta-analysis 
Large studies 
only* 
8 2609 1259 1.30 0.88-1.92 61.2 0.0117 
CR 
ALL LAXATIVES 24 1661 1498 1.30 0.95-1.78 45.3 0.0090 
PEG 19 1154 1305 1.34 0.91-1.97 50.6 0.0061 
81 
 
NaP 7 309 340 0.83 0.45-1.51 54.2 0.0414 
Other laxatives 4 198 193 1.21 0.67-2.16 0 0.5659 
Laxatives given 
before SBCE only 
21 1559 1382 1.26 0.90-1.76 48.6 0.0068 
With simethicone 7 358 289 1.10 0.68-1.86 0 0.4624 
No simethicone 19 1303 1259 1.31 0.90-1.91 52.3 0.0042 
Low risk of bias 
only 
10 535 481 1.33 0.93-1.91 26.4 0.2006 
Large studies 
only 
15 1417 1292 1.25 0.85-1.84 58.4 0.0023 
Abbreviations: CI confidence interval, CR completion rate, DY diagnostic yield, NaP sodium phosphate, OR odds 
ratio, PEG polyethylene glycol, SB small bowel, SBCE small bowel capsule endoscopy, SBVQ small bowel visualisation 
quality 





(i) Overall use of laxatives vs no laxatives for bowel preparation 
Primary outcomes: Diagnostic yield 
DY (all SB findings): Overall, 26 studies (1816 patients)139,140,155,157,159–
163,166,167,169,141,170,172,173,176–178,142,145,147,148,150,152,154 were analyzed for the pooled proportion of 
SB findings. 58% of SBCE had SB findings (95%CI 52-64%; I2=80.9, p<0.0001). 19 
studies139,140,157,159,162,163,166–168,176,178,141,142,145,147,148,150,152,155 examined DY of all findings in 1139 
patients who received laxatives compared to those (1188 patients) who did not. In the group 
given laxatives, the OR for having any SBCE findings was 1.11 (95%CI 0.85-1.44; I2=39.1%, 
p=0.04) Figure 5.2. The random effects model was used. There was no significant publication 
bias (Egger’s test p=0.15). 
DY (significant SB findings): Overall, 19 studies (1584 
patients)141,142,161,163,167,168,170,172,173,176,177,147,148,150,154,155,157,159,160 were analyzed for the pooled 
proportion of significant findings. 45% of SBCE had significant SB findings (95%CI 39-52%; 
I2=82.7%, p<0.0001). 12 studies141,142,168,176,147,148,150,155,157,159,163,167 examined the DY of 
significant findings in 904 patients who received laxatives, compared to 987 patients who did 
not receive laxatives. In patients given laxatives, the OR for SBCE with significant findings was 
1.1 (95%CI 0.76-1.60; I2=60.2%, p=0.004), Figure 5.3. The random effects model was used. 





Figure 5.2: Pooled OR of all SB findings when laxatives were used vs no laxatives. (a) Forest 















Figure 5.3: Pooled OR of significant SB findings when laxatives were used vs no laxatives. (a) 




















SBVQ: Overall, 16 studies (2979 patients) 140,141,171,172,174,176,177,142,145,146,151,156,157,164,168 were 
analysed for the pooled proportion of SBCE considered to have adequate visualization. Of 
those, 68% SBCE were considered to have adequate bowel preparation (95%CI 59-76%; 
I2=91.5, p<0.0001). SBVQ with laxatives was examined in 13 studies (2767 
patients)140,141,171,174,176,142,145,146,151,156,157,164,168, as compared to SBVQ when no laxatives were 
used (n=1354). The OR of adequate SBVQ was 1.60 without laxatives compared to patients 
who received laxatives (95%CI 1.08-2.36; I2=64.9%, p=0.0006), Figure 5.4. The random effects 
model was used; however no significant publication bias was found (Egger’s test, p=0.103). 
The pooled risk difference was 0.07 (95% CI 0.01-0.13; I2=74.4%, p<0.0001), giving a NNT of 
14 (95%CI 8-68). 
CR: Overall, 30 studies139,140,154,155,157–160,162–165,141,166–170,172,174–176,178,142,145–148,150,151 with 2159 
patients were analyzed for pooled SBCE CR. The overall CR was 84% (95%CI 81-87%; I2=66.6%, 
p<0.0001). 24 studies139,140,155,157–159,162–164,166–168,141,174–176,178,142,145–148,150,151 examined CR in 
1661 patients who received laxatives compared to 1498 patients who were not given 
laxatives. The OR for completed SBCE examinations was 1.30 (95%CI 0.95-1.78; I2=45.3%, 
p=0.009) between the two groups, Figure 5.5. The random effects model was used due to 




Figure 5.4: Pooled OR of having improved SBVQ when laxatives were used vs no laxatives. 
























Figure 5.5: Pooled OR of completed SB examination when laxatives were used vs no 





























(ii) PEG and NaP 
DY: For patients given PEG, the pooled OR for all SB findings was 0.90 (95%CI 0.74-1.10; 
I2=27.6%, p=0.17). The pooled OR for all findings in patients given NaP was 1.40 (95%CI 0.88-
2.22; I2=0%, p=0.49). 
SBVQ: The OR of adequate visualisation in patients given PEG was 1.44 (95%CI 1.01-2.06; 
I2=53.4%, p=0.02). The pooled risk difference was 0.02 (95%CI -0.04-0.08; I2=71.2%, 
p=0.0001); NNT for PEG = 53 (95%CI -25-12).  
Patients given NaP had an OR for adequate visualisation of 2.10 (95%CI 1.03-4.29; I2=77.1%, 
p=0.0006). The pooled risk difference was 0.16 (95%CI 0.02-0.30; I2=79.2%, p=0.0002); NNT 
for NaP = 7 (95%CI 4-50). 
CR: The pooled OR for completion in patients given PEG was 1.34 (95%CI 0.91-1.97; I2=50.6%, 
p=0.006), compared to a pooled OR of 0.83 (95%CI 0.45-1.51; I2=54.2%, p=0.04) in patients 
given NaP. 
Further subgroup analyses for the different PEG dosages, i.e. low volume (<2L PEG), 2L PEG 




Table 5.4: Subgroup analyses for different PEG dosing regimes 













DY for all SB findings 
2L PEG 16 1024 56 51-62 61.3 
<2L PEG 4 136 67 52-79 64.4 
>2L PEG 3 134 44 22-69 76.9 
PEG given 
before CE 
17 1218 56 50-62 69.7 
With 
simethicone 
6 235 63 56-69 41.1 
No simethicone 16 1059 54 48-61 71.2 
DY for significant SB findings 
2L PEG 15 1007 44 37-50 70.0 
<2L PEG Insufficient data for meta-analysis 
>2L PEG Insufficient data for meta-analysis 
PEG given 
before CE 
15 1162 43 36-50 77.7 
With 
simethicone 
5 195 48 41-55 52.6 
No simethicone 13 994 43 35-52 82.0 
SBVQ (proportion of studies where adequate visualisation was achieved) 
2L PEG 10 1883 64 50-76 93.3 
<2L PEG  Insufficient data for meta-analysis 
>2L PEG Insufficient data for meta-analysis 
PEG given 
before CE 
11 909 64 48-78 93.3 
With 
simethicone 
5 197 72 51-86 83.2 
No simethicone 12 2360 58 44-71 92.9 
      
CR 
2L PEG 16 1077 85 80-90 72.9 
<2L PEG 7 245 86 80-90 0 
>2L PEG 4 226 79 73-84 0 
PEG given 
before CE 
20 1452 85 81-88 69.6 
With 
simethicone 
9 328 86 81-89 36.7 
No simethicone 18 1240 85 80-88 66.6 
Abbreviations: CE capsule endoscopy, CI confidence interval, CR completion rate, DY diagnostic yield, PEG 






















those not given 
laxatives 
95%CI I2 (%) 
(heterogeneity) 
DY for all SB findings 
2L PEG 9 638 817 0.84 0.68-
1.04 
38.4 
<2L PEG 4 136 129 1.28 0.76-
2.14 
0 
>2L PEG Insufficient data for meta-analysis 
DY for significant SB findings 
2L PEG 9 638 817 1.01 0.63-
1.63 
62.2 
<2L PEG Insufficient data for meta-analysis 
>2L PEG Insufficient data for meta-analysis 
SBVQ (proportion of studies where adequate visualisation was achieved) 
2L PEG 6 573 687 1.21 0.66-
2.21 
63.1 
<2L PEG Insufficient data for meta-analysis 
>2L PEG Insufficient data for meta-analysis 
CR 
2L PEG 11 763 977 1.09 0.59-
2.03 
66.0 
<2L PEG 6 225 190 2.03 1.21-
3.40 
0 
>2L PEG 3 126 155 1.13 0.61-
2.07 
0 
Abbreviations: CI confidence interval, CR completion rate, DY diagnostic yield, OR odds ratio, PEG polyethylene 









(iii) Timing of laxative administration 
There were insufficient data to carry out an analysis of studies where laxatives were given 
post-SBCE ingestion; therefore the group of patients where laxatives were given only before 
SBCE ingestion was meta-analysed. 
DY: The pooled OR of having SB findings was 1.12 (95%CI 0.85-1.48; I2=41.3%, p=0.04) in 
patients given laxatives only prior to SBCE. There was insufficient data for the meta-analysis 
of the OR of significant SB findings. 
SBVQ: The pooled OR of adequate visualization in patients given laxatives before SBCE was 
1.83 (95%CI 1.07-3.12; I2=71.8%, p=0.0002). 
CR: The pooled OR of completed SBCE examinations was 1.26 (95%CI 0.90-1.76; I2=48.6%, 
p=0.007) in this group of patients. 
 
5.3.4 Sensitivity analyses 
Further sensitivity analyses were conducted and are detailed in Table 5.5. Please also see the 
appendices for a table detailing the studies included in each subgroup analysis. 
Retrospective vs Prospective studies: The pooled ORs for the DYs of retrospective studies 
and prospective studies did not differ significantly when DY for all findings (p=0.13) and 
significant findings only (p=0.14) were examined. SBVQ also did not differ significantly 
between retrospective and prospective studies (p=0.13). There was a significant difference 
in pooled OR for completion between retrospective and prospective studies (p=0.001). 
Retrospective studies showed a higher pooled OR for completion; however moderate to high 
heterogeneity was seen in the group of retrospective studies despite methodical study 
exclusion, in contrast to the low heterogeneity in the prospective studies. 
Use of simethicone: Pooled ORs for DY of both overall (p=0.21) and significant findings 
(p=0.23) did not differ significantly whether simethicone was used or not. There were also 




Studies at low risk of bias vs studies at moderate-high risk of bias: When comparing studies 
at low risk of bias against those at moderate to high risk of bias, there were no significant 
subgroup differences for DY of all findings (p=0.74) and significant findings (p=0.29). SBVQ 
and CR also did not differ significantly between the subgroups (p=0.65 and p=0.50 
respectively). 
Large studies vs small studies: There was no significant difference in OR for DY overall 
(p=0.93) or for significant findings only (p=0.97). Furthermore, neither SBVQ nor CR differed 
significantly between the subgroups (p=0.19 and p=0.96 respectively). However it was noted 
that the large studies with 30 or more patients in both laxative and control groups showed 





Table 5.5: Summary of sensitivity analyses 













those not given 
laxatives 
95%CI I2 (%) 
(heterogeneity) 
1. Retrospective vs Prospective studies 
1.1 DY for all SB findings 
Retrospective 7 559 655 0.88 0.69-1.11 41 
Prospective 12 580 533 1.15 0.89-1.47 35 
Test for subgroup 
differences 
Chi2=2.35; p=0.13, I2=57.4% 
1.2 DY for signficant SB findings 
Retrospective 2 386 516 0.79 0.61-1.03 0 
Prospective 10 518 471 1.18 0.74-1.88 61 
Test for subgroup 
differences 
Chi2=2.16; p=0.14, I2=53.8% 
1.3 SBVQ 
Retrospective 7 2312 1073 1.23 0.75-2.02 65 
Prospective 6 455 281 2.20 1.26-3.84 44 
Test for subgroup 
differences 
Chi2=2.33; p=0.13, I2=57.1% 
1.4 CR 
Retrospective 8 697 730 2.26 1.62-3.15 63 
Prospective 16 964 768 1.11 0.85-1.44 1 
Test for subgroup 
differences 
Chi2=10.91; p=0.001, I2=90.8% 
2. Simethicone vs no simethicone 
2.1 DY for all SB findings 
Simethicone 5 201 203 1.25 0.83-1.89 46 
No simethicone 15 938 1005 0.94 0.78-1.14 34 
Test for subgroup 
differences 
Chi2=1.56; p=0.21, I2=36.1% 
2.2 DY for significant SB findings 
Simethicone 3 125 124 0.78 0.46-1.32 0 
No simethicone 10 779 883 1.19 0.76-1.87 66 
Test for subgroup 
differences 
Chi2=1.45; p=0.23, I2=31.0% 
2.3 SBVQ 
Simethicone 3 84 82 2.31 0.53-10.05 68 
No simethicone 12 2683 1318 1.53 1.04-2.25 63 
Test for subgroup 
differences 
Chi2=0.29; p=0.59, I2=0% 
2.4 CR 
Simethicone 7 358 289 1.10 0.68-1.76 0 
No simethicone 19 1303 1259 1.54 1.23-1.92 52 
Test for subgroup 
differences 








3. Low risk of bias vs mod-high risk of bias 
3.1 DY for all SB findings 
Low risk of bias 7 317 327 0.95 0.68-1.32 38 
Mod-high risk of bias 12 822 861 1.01 0.83-1.24 44 
Test for subgroup 
differences 
Chi2=0.11; p=0.74, I2=0% 
3.2 DY for significant SB findings 
Low risk of bias 5 207 260 0.83 0.42-1.63 58 
Mod-high risk of bias 7 697 727 1.31 0.80-2.15 67 
Test for subgroup 
differences 
Chi2=1.14; p=0.29, I2=12.2% 
3.3 SBVQ 
Low risk of bias 2 87 46 2.16 0.49-9.59 70 
Mod-high risk of bias 11 2680 1308 1.50 1.00-2.25 65 
Test for subgroup 
differences 
Chi2=0.21; p=0.65, I2=0% 
3.4 CR 
Low risk of bias 10 535 481 1.33 0.93-1.91 26 
Mod-high risk of bias 14 1126 1017 1.55 1.21-1.98 56 
Test for subgroup 
differences 
Chi2=0.45; p=0.50, I2=0% 
4. Large vs smaller studies 
4.1 DY for all SB findings 
Large studies 10 845 975 0.99 0.82-1.20 65 
Smaller studies 9 294 213 1.01 0.68-1.49 0 
Test for subgroup 
differences 
Chi2=0.01; p=0.93, I2=0% 
4.2 DY for significant SB findings 
Large studies 8 769 896 1.11 0.68-1.80 73 
Smaller studies 4 135 91 1.09 0.62-1.93 0 
Test for subgroup 
differences 
Chi2=0.00; p=0.97, I2=0% 
4.3 SBVQ 
Large studies 8 2609 1259 1.30 0.88-1.92 61 
Smaller studies 5 158 95 2.56 1.01-6.48 61 
Test for subgroup 
differences 
Chi2=1.74; p=0.19, I2=42.7% 
4.4 CR 
Large studies 15 1426 1292 1.43 1.14-1.78 58 
Smaller studies 9 244 206 1.41 0.88-2.26 6 
Test for subgroup 
differences 
Chi2=0.00; p=0.96, I2=0% 
Abbreviations: CI confidence interval, CR completion rate, DY diagnostic yield, OR odds ratio, PEG polyethylene 






To date, the ideal preparation for SBCE has been a matter of several meta-analyses and 
clinical trials with contradictory results. Bowel preparation with laxatives is often regarded 
the least tolerable part of the procedure, as repeatedly shown in colonoscopy studies179,180. 
The high PEG volume makes it difficult to ingest and can cause fluid overload in susceptible 
patients181,182. NaP has its own accompanying risks including hyperphosphataemia183–185 and 
comes with warnings from several national drug regulatory authorities186. It would therefore 
be desirable to abandon laxatives in SBCE, especially if no adverse effect on DY can be 
confirmed. Therefore, the major questions regarding the use of bowel preparation in SBCE 
are: (a) Do laxatives improve DY and/or SBVQ; and (b) If laxatives are given, what is the 
optimal timing, i.e. before or after CE ingestion. 
 
5.4.1 Whether laxatives improve DY and/or SBVQ 
Due to the randomness of capsule movement in the gut, DY is largely dependent on the 
percentage of mucosa visualized as well as the clarity of the obtained images66,133. However, 
DY is also affected by many other factors such as patient case mix and thresholds for SBCE 
referral at different centers, in addition to the experience and reporting confidence of 
individual SBCE readers187–189. On the other hand, SBCE technology has now markedly 
improved and most commercially available capsules offer higher definition, increased frame-
rate and a 12-hour recording time with real-time viewer capacity.  
This analysis shows that the use of laxatives in SBCE did not significantly improve the 
detection of SB findings overall, nor significant SB findings, independent of type of laxatives 
used. The OR for SBCE DY (1.11) was lower in our meta-analysis compared to previous meta-
analyses68–71,132, likely due to the significantly larger size of this meta-analysis, Table 5.6. It 
was evident that there is still a lack of clear definition for DY in SBCE. Most of the included 
studies classified SBCE findings as “positive/definite/diagnostic” and “suspicious/probable 
cause of symptoms”; these classifications are inconsistent and/or not specified across 
studies. Attempts to standardize the reporting of SBCE findings93,190–192 remain unvalidated 













Pooled OR (95%CI) 
Niv, 2008 (7) DY - - - 
SBVQ 5 130/107 Results not reported as OR. 
Pooled proportion for 
adequate visualization: 
78% in pts given laxatives vs 
49% in pts not given 
laxatives. 
Rokkas et al, 
2009 (5) 
DY 5 263/213 1.81 (1.25-2.63) 
SBVQ 7 404/249 2.11 (1.25-3.57) 
Belsey  et al, 
2012 (2) 
DY 5 Ns 1.88 (1.24-2.84) 
SBVQ 8 424/322 2.31 (1.46-3.63) 
Song et al, 
2013 (6) 
*PEG only 
DY 5 145/148 1.97 (1.20-3.24) 
SBVQ 4 174/173 4.02 (0.71-8.24) 
Kotwal et al, 
2014 (4) 




PEG: 1.68 (1.16-2.42) 
NaP: 1.77 (1.18-2.64) 




PEG: 3.13 (1.70-5.75) 




DY 19 1139/1188 1.11 (0.85-1.44) 
SBVQ 13 2767/1354 1.60 (1.08-2.36) 
Abbreviations: CI confidence interval, DY diagnostic yield, NaP sodium phosphate, ns not specified, OR odds ratio, 
PEG polyethylene glycol, SBVQ small bowel visualization quality  
 
The use of SBVQ as an outcome measure is subject to the same limitations, as there remains 
no clear consensus on what constitutes “adequate” visualization quality. To circumvent this 
we applied stringent measures for determining SBVQ in studies where the exact definition of 
good visualization was not specified. For example, if a study reported results as ratings of 
“excellent”, “good”, “fair” and “poor” (or similar), only “excellent ” and “good” ratings were 
considered adequate. Recently, Ponte et al193 examined various SBVQ scales and concluded 
that where the entire SBCE video was examined results may be more consistent and 
accurate. They also suggested that computer-assisted grading scales194,195, when adequately 
developed, are likely to be more objective than operator-dependent grading scales196.  
Despite its drawbacks, SBVQ remains a key quality indicator for SBCE, a purely image-based 
technique, regarded a surrogate marker of the reader’s confidence in detecting and 
characterizing SB findings. SBVQ improved slightly in certain subgroups, namely studies with 
NaP, and simethicone alongside laxatives. Simethicone has previously been shown to 
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improve SBVQ197,198. Therefore, a NNT of 14 required to achieve adequate SBVQ in one 
additional patient suggests that there may be a possible benefit with laxatives that may have 
been underestimated due to the aforementioned sources of heterogeneity. Nevertheless, 
analyzing the effects of the 2 main subgroups of laxatives, the OR of NaP achieving adequate 
SBVQ was 2.01 (NNT=7), whereas PEG alone had a lower OR of 1.44 and much higher NNT of 
53. The high NNT observed with PEG calls into question the utility of this preparation in the 
everyday clinical practice, at least with conventional administration schedules. 
 
5.4.2 Whether laxatives should be given for SBCE examination 
Interestingly, Adler et al173 recently proposed that although fasting alone results in adequate 
proximal SB images; the distal SB is often less well prepared, a consistent finding from other 
studies. They found that post-SBCE Na picosulphate improved distal SB visualization 
compared to conventional 2L PEG (p<0.0001). Hence, they advocate the administration of 
laxatives post SBCE ingestion. The use of booster doses of laxatives post capsule ingestion in 
capsule colonoscopy has been shown to improve large bowel visualization199,200.  
At present, there is inadequate data to perform a subgroup analysis for laxative 
administration post-capsule ingestion. However, in order to gauge this, a subgroup analysis 
was carried out, examining only the studies where laxatives were given prior to SBCE. As this 
pooled OR for DY (1.12) is similar to that of the overall analysis of all laxatives and dose 
timings (1.11), it can be inferred that the studies where laxatives were given post-SBCE or in 
split doses before and after capsule ingestion did not make a great difference in DY. 
Nevertheless, further studies on this issue are certainly warranted. 
A significant proportion of patients (10-20%) still have incomplete SBCE with potential impact 
on DY. Therefore the effect of laxatives on SBCE CR was also examined. These results show 
that the administration of laxatives did not impact on CR, regardless of the type of laxative, 
administration schedule or the dosage. However, this meta-analysis captured studies 
conducted over 12 years, and technological improvements, as well as differences between 






 5.4.3 Cost-effectiveness 
Any changes to patient preparation which increase cost-effectiveness without compromising 
quality of clinical investigation are desirable. Performing SBCE without the administration of 
bowel preparation could be advantageous not only for patients, but also for healthcare 
providers. Potential cost savings, based on the current edition of the British National 
Formulary (BNF)201, for a center performing 100 capsules/year are reported in Table 5.7. 
Further cost savings could also result from avoiding pre-admission of certain patient groups, 
e.g. elderly patients with multiple comordibities, for bowel preparation. Recently, 
Triantafyllou et al202 found that following implementation of austerity measures in Greece, 
the number of SBCEs performed decreased and indications were rationalized to maximize 
yield.  
Table 5.7: Estimated costs of different types of laxatives 
Laxative Definition of 1 dose Cost of 1 dose Cost of 100 doses 
PEG as Moviprep® 
(Norgine) 
2 pairs of sachets in 2L 
water, either single or 
split dose 
£9.87 £987.00 
NaP as Fleet 
Phospho-soda® 
(Casen-Fleet) 
2 x 45ml in split dose £4.79 £479.00 
Picosulphate with 
MgC as Picolax® 
(Ferring) 
2 sachets in split dose £3.39 £339.00 
Abbreviations: MgC magnesium citrate, NaP sodium phosphate, PEG polyethylene glycol  
 
5.4.4 Limitations 
An important limitation of this meta-analysis is the statistical heterogeneity. An attempt was 
made to address this by performing subgroup analyses; however, the heterogeneity may also 
be due to the lack of standardized definitions for outcome measures, as previously discussed. 
Another significant cause of heterogeneity is the mix of study types including both 
prospective and retrospective studies, in the forms of randomised controlled trials and 
observational cohort studies. Due to lack of sufficient data, certain subgroups, including 
indications for SBCE or timing of laxative administration, could not be statistically analysed. 
Furthermore, the “control” group of patients who did not receive pre-SBCE laxatives included 
a range of fasting regimens, from liquid diets or a straightforward fast, to low-residue diets 




This review and meta-analysis suggests that the use of laxatives did not significantly improve 
diagnostic yield or completion rate of SBCE, but did marginally increase SBVQ. Although no 
effect of laxatives on diagnostic yield was noted, the effect on SBVQ suggests that the use of 
laxatives in SBCE may be beneficial where there is increased likelihood of subtle findings such 
as mucosal aphthae and small growths. There is emerging anecdotal evidence, especially 
from the use of the colon capsule, that one or more additional doses of laxatives given after 
capsule ingestion can improve SBVQ and potentially diagnostic yield in the distal SB to colon. 
Based on this meta-analysis, there is limited evidence to support the use of laxatives in SBCE 
which remains fairly dependent on individual preference or local practices. In the process of 
this work, the need to develop standardized objective visualization scoring and recording of 







Chapter 6 Timing of CE in relation to diagnostic pathway for GI bleeding 
The previous chapters have examined the data on various methods to improve image quality 
and bowel visualisation in CE. In this chapter, the focus now widens to ways in which we can 
utilise CE more effectively in the clinical setting, starting by examining how the timing of CE 
in the investigation pathway for patients with SBB can contribute to its diagnostic value, and 
to optimising both patient care and resource use. 
 
6.1 Introduction 
As an investigation for SBB, CE is usually performed non-acutely as an outpatient procedure; 
however as previously discussed, there is now evidence that performing CE closer to the 
index bleeding episode – ideally within the first 72h of presentation – increases its diagnostic 
yield36. This is corroborated by studies showing that for the same indications, inpatient CE 
has a higher diagnostic yield compared to outpatient procedures 37–39.  
At present the role of CE in patients presenting acutely with suspected SBB is often as the 
“next-line” investigation following after negative bidirectional endoscopy. However, 
although the rationale for UGIE as a first-line investigation remains undisputed due to its 
ability to both diagnose and treat, performing colonoscopy in the acute setting is a 
demanding task both for the patient and clinician, and is often limited by the quality of bowel 
preparation and patient fitness or tolerance. Furthermore anecdotally it has been observed 
that the logistics of scheduling urgent inpatient colonoscopies often causes longer hospital 
stays. At our large tertiary care hospital, there has been a trend for performing CE following 
a negative index UGIE alone, with anecdotal evidence that by doing so unnecessary 
colonoscopies have been avoided in certain patients. Therefore, this study aimed to examine 
the effect of earlier investigation with CE for inpatients with suspected SBB manifesting as 
melaena or severe IDA. The primary outcome was to assess in patients with suspected SBB 
and negative initial UGIE, whether the use CE prior to inpatient colonoscopy reduced the 






 6.2.1 Patient selection 
This was a retrospective study of all inpatient CEs carried out at our tertiary care academic 
centre from March 2005 to March 2017, using a prospectively-designed and continuously-
maintained database. Data collected were: 
 Patient demographics: age, gender 
 Relevant past medical history: cardiovascular, liver and/or renal disease; use of 
antiplatelet and/or anticoagulant medications; any previous episodes of GI bleeding; 
 Circumstances of admission; 
 CE indications and findings; 
 Timing of CE relative to admission and prior conventional endoscopies; 
 Conventional endoscopies carried out within the past 6 months prior to admission; 
 Further investigations and results; 
 Patient outcomes, defining follow-up period as the date of last recorded patient contact 
with local healthcare services, discharge (back) to another health board, or death. 
Inpatients undergoing CE for suspected SBB were included. Suspected SBB was defined as 
IDA or melaena in patients with negative UGIE, with no other signs or symptoms suggesting 
lower GI tract pathology such as frank rectal bleeding, diarrhoea with associated significant 
weight loss or lower abdominal pain. Over the study period, patients admitted with UGIE-
negative IDA or melaena underwent CE either following nondiagnostic bidirectional 
endoscopy (referred to as “Group 1”), or following only negative UGIE (“Group 2”), based on 
the senior clinician-in-charge’s individual investigative pathways.  
 
 6.2.2 CE procedure 
CE was carried out with one of two commercially-available CE systems, PillCam®SB1/2 
(Given®Imaging Ltd, now Medtronic, Minneapolis, Minnesota, USA) or Mirocam® 
(Intromedic, Seoul, South Korea). SB preparation was dependent on timing of CE relative to 
UGIE or colonoscopy, as well as the overall patient condition. In general, our centre’s protocol 
has been to use 2L PEG, although an overnight fast alone was sometimes used for frailer 
patients. If CE was carried out immediately after colonoscopy, additional bowel preparation 
beyond the 2L PEG used for colonoscopy was not given. Simethicone was administered with 
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all CEs; use of prokinetics was guided by evolving practice guidelines and individual patient 
need198. Over this time period, CEs were read and reported by one of three experienced 
readers based at our centre using the relevant proprietary software. Speed and reading 
conditions varied as per individual preference. Significant CE findings were those deemed 
causative of the patient’s presentation; this was determined by the senior treating clinician 
as they were best placed to weigh up the clinical presentation against the pathology seen. 
Significance of lesions seen was routinely recorded in the capsule report and/or patient 
casenotes at our centre. Significant findings included: vascular lesions (e.g. angioectasias), 
areas of fresh and ongoing bleeding seen at the time of CE, inflammatory lesions (e.g. ulcers, 
aphthae and strictures), various enteropathies such as NSAID-related enteropathy or portal 
hypertensive enteropathy, and discrete bleeding mass lesions. Over the study period, all CEs 
carried out at our centre have been recorded in a prospectively-designed database with the 
above details noted to be correct at time of CE. 
 
 6.2.3 Statistical analysis 
Continuous data is reported as mean±standard deviation (SD) or median (range) where 
appropriate. Statistical analyses were carried out and normality of distributions was tested 
by plotting histograms using the Analysis Toolpak in Microsoft® Excel 2010 (Microsoft 
Corporation, Washington, USA). For normally distributed data, Student’s T-test (when n<30) 
or the Z-test (when n≥30) were used to compare means, whereas the Mann-Whitney U-test 
was used for data where a normal distribution could not be assumed. The Chi-square test 
was used to compare proportions for discrete data variables. A p-value of <0.05 was taken 
to denote statistical significance. No specific institutional ethical approval was required for 
this study as the data used had been collected in the course of routine patient care; ethical 
approval has been granted to the unit as a whole for the safe, confidential collection and 






 6.3.1 Characteristics of included patients 
Over the period from March 2005-March 2017, 170 inpatients underwent CE for suspected 
small bowel bleeding (104M/66F, mean age 65.8±17.1 years). Forty-four patients had IDA 
and 126 had melaena. Mean haemoglobin level (Hb) at presentation was 82.8±22.4g/l. In 
total, there were 6 incomplete CEs; 2 were retained and required endoscopic or surgical 
retrieval. The median follow-up time was 31.1 months (range 0.03-121.4 months); however 
it must be noted that this was a continuously-maintained database and follow-up times 
depended on the time from CE to data collection for each patient. 
Patients were divided into 2 groups for analysis of outcomes (Figure 6.1). Group 1 comprised 
those with negative bidirectional endoscopy, while Group 2 included those with only negative 
UGIE. The groups had similar admission Hb, demographics, and medical history; they were 









CE following –ve UGIE only 
48M/ 27F; mean age 64.7 ± 19.8 yrs 
Group 1 
CE following –ve bidirectional endoscopy 
57M/ 38F; mean age 66.7 ± 14.6 yrs 
+ve CE (n=50) 
Gastric findings: 11 
Colon findings: 12 
-ve CE (n=45) 
Insignificant findings: 
5 (gastric) 
+ve CE (n=39) 
Gastric findings: 9 
Colon findings: 10 
-ve CE (n=36) 
Insignificant findings: 
3 gastric, 1 colon 
Rpt UGIE: 6 Rpt UGIE: 4 
Colon Ix 
Colonoscopy: 50 
Rpt colonoscopy: 4 
CT colon: 1 
Colon Ix 
Colonoscopy: 45 
Rpt colonoscopy: 2 
CT colon: 1 
Rpt UGIE: 9 Rpt UGIE: 1 
Colon Ix 
Colonoscopy: 10 
CT colon: 0 
Colon Ix (ongoing 
bleeding) 
Colonoscopy: 15 
CT colon: 1 
-ve colonoscopy (n=95) no colonoscopy (n=75) 
CE referral 
Total burden of colon Ix: 
103 colon Ix 
in 95 episodes of IDA/melaena 
Ix per episode: 1.08 
Diagnostic yield: 3.9% (4/103) 
Total burden of colon Ix: 
26 colon Ix 
in 75 episodes of IDA/melaena 
Ix per episode: 0.35 
Diagnostic yield: 53.8% (14/26) 
March 2005-March 2017: 2019 CEs; 264 (13.1%) inpatients 
170 inpatients with IDA and melaena 
All patients: initial -ve UGIE (n=170) 
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Table 6.1: Comparison of patient characteristics between patients undergoing CE following 
negative bidirectional endoscopy and patients undergoing CE following negative UGIE only 
 Group 1: CE after 
negative bidirectional 
endoscopy 
Group 2: CE after negative 
UGIE only 
P-value 
Total number 95 75  
M/F 57M/ 38F 48M/ 27F 0.59 
Age; years (mean±SD) 66.7 ± 14.6 64.7 ± 19.8 0.46 
PMH 
Liver disease 15 11 0.84 
Cardiovascular disease 46 29 0.20 
On anticoagulants/ antiplatelets 37 
24 on anticoagulants 
17 on antiplatelets 
23 
10 on anticoagulants 
13 on antiplatelets 
0.26 
Renal disease 10 9 0.76 
Previous episode/s of GI bleeding 28 24 0.72 
Admission details 
OGIB (%) 48 50 0.03 
IDA (%) 28 16 0.23 
Other (%)  19 9 0.16 
Symptomatic from blood loss (%) 31  




(14 with haemodynamic 





Admission Hb; g/L (mean±SD) 82.8 ± 20.7 82.9 ± 24.6 0.98 
Length of time from admission to CE; 
days (mean±SD)* 
6.38 ± 3.80 (n=68) 5.08 ± 3.80 (n=66) 0.02 
Total length of admission; days  
(mean±SD)* 
12.5 ± 11.4 (n=68) 10.5 ± 9.58 (n=66) 0.04 
Follow-up time after CE**; months 
(mean±SD) 
37.9 ± 31.5 35.8 ± 31.9 0.62 
CE findings 
Positive CE (%) 50 39 0.93 
Negative CE (%) 45 36  
Incomplete CEs 3 3 0.77 
Abbreviations: CE capsule endoscopy; Hb haemoglobin; IDA iron deficiency anaemia; OGIB obscure gastrointestinal 
bleeding; PMH past medical history; SD standard deviation 
*These calculations include only from patients admitted specifically for OGIB/IDA; i.e. excluding patients admitted 
electively or with unrelated initial presentations. 
**Follow-up as recorded in electronic hospital records – i.e. until time of last recorded patient contact, discharge 










Patients in Group 2 were significantly more likely to have been admitted with melaena and 
were also significantly more symptomatic from blood loss at the time of admission.  
Outcomes and further investigations carried out within the two groups are summarised in 
Table 6.2. 
 
Table 6.2: Investigations and management in the included group of inpatients with 
IDA/melaena 
 Group 1: 
CE following -ve bidirectional endoscopy 
Group 2: 
CE following -ve UGIE only 
CE findings +ve CE - ve CE +ve CE -ve CE 
Number of pts (%) 50 (52.6) 45 (47.4) 39 (52.0) 36 (48.0) 
Incomplete CEs (%) 3 (3.2) 3 (4.0) 
UGIE and Colonoscopy 
Missed findings on 
initial UGIE (%) 
11 (22.0) 5 (11.1) 
*all insignificant 
9 (23.1) 3 (8.3) 
*all insignificant 
Missed findings on 
initial colonoscopy 
(Group 1) (%) 
12 (24.0) - NA 
Colon findings on 
CE (Group 2) (%) 
NA 10 (25.6) 1 (2.8) 
*insignificant 
Repeat UGIEs (%) 6 (12.0) 4 (8.9) 9 (23.1) 1 (2.8) 
Total number of 
colon procedures/ 
Ix carried out 
Initial colonoscopy: 50 
Repeat colonoscopy: 4 
CT colon: 1 
Total: 55 
 
Initial colonoscopy: 45 
Repeat colonoscopy: 2 
CT colon: 1 
Total: 48 
Initial colonoscopy: NA 
Colonoscopy: 10 
CT colon: 0 
Total: 10 
Initial colonoscopy: NA 
Colonoscopy: 15 
CT colon: 1 
Total: 16 
Total burden of 
colon Ix 
103 colon Ix for 95 episodes 26 colon Ix for 75 episodes 
Diagnostic yield of 
colon Ix 
3.9% (4/103) 53.8% (14/26) 
Other Ix and/or management following CE 
DBE (%) 7  (14.0) - 9 (23.1) - 
CT angiography (%) 5 (10.0) 3 (6.7) 1 (2.6) 2 (5.6) 
Repeat CE (%) - - 2 (5.1) - 
Surgery (%) 5 (10.0) 2 (4.4) 4 (10.3) - 
Abbreviations: -ve negative; +ve positive; CE capsule endoscopy; DBE double balloon enterography; Ix 





6.3.2 CE findings and outcomes: Group 1 
In Group 1, there were 95 CEs carried out following negative bidirectional endoscopy. There 
were significant CE findings in 50 patients, i.e. diagnostic yield 52.6%. Of these patients, 46 
had SB findings; 17/46 patients had additional non-SB findings detected by CE in the stomach 
(n=9; duodenitis, gastritis and GAVE), colon (n=6; all angiodysplasias and/or bleeding) or both 
(n=2). Another 4 patients had normal SB but colon findings seen on CE which were deemed 
relevant. Forty-five patients had nondiagnostic CE following negative bidirectional 
endoscopy. In 31, the SB was reported as normal whereas the other 14 had nonspecific 
findings thought unlikely to be of clinical significance. The indication for CE was melaena in 
67 patients and IDA in 28. The proportions of patients with melaena and IDA with or without 
significant CE findings were not significantly different (see Table 6.2). Table 6.3 gives the 
breakdown of CE findings in this group. 
 
Table 6.3: Breakdown of CE findings in Group 1 
Significant CE Findings (n=50) 
Type of findings Number of patients (%) 
AVM/angiodysplasia 18 (36%) 
Free blood/active bleeding 10 (20%) 




PHE including SB varices 9 (18%) 
SB inflammation 2 (4%) 
Significant-appearing SB lesion e.g. polypoid 
masses 
5 (10%) 
Normal SB but findings elsewhere in gut 4 (all colonic bleeds/AVMs) (8%) 
Nondiagnostic CE Findings (n=45) 
Type of findings Number of patients (%) 
Normal capsule endoscopy 31 (69%) 
AVM not deemed clinically significant 6 (13.3%) 
Nonspecific changes/findings e.g. mild 











Therefore, in this group CE found a total of 16/95 (16.8%) gastric findings which had been 
missed on initial UGIE. Ten patients had repeat UGIE; in 9/10 the UGIE was done to further 
investigate or manage lesions seen on CE while 1 was a “second look”. There were missed 
colon findings in 12/95 (12.6%) patients, of whom 3 required repeat colonoscopy for APC; 
the others were managed conservatively for confirmed or likely diverticular bleeds. A further 
3 patients had repeat colonoscopies due to re-bleeding and/or ongoing bleeding, i.e. 6/95 
patients had repeat colonoscopies. Two patients underwent CT colonography following CE. 
Double balloon enteroscopy (DBE) was performed on 7 patients in this group to manage SB 
lesions seen on CE. Seven patients required surgery to investigate discrete lesions seen on 
CE (n=3) or to manage continued bleeding (n=4). 
 
 
6.3.3 CE findings and outcomes: Group 2 
In Group 2, seventy-five CEs were performed in patients who had negative UGIE only, with a 
diagnostic yield of 39/75 (52.0%). In the 39 patients with significant CE findings, 6/39 had 
normal SB but significant non-SB findings in the stomach (n=2) and colon (n=4). Of the 33 
patients with SB findings on CE, 9/33 had additional non-SB findings in the stomach (n=3), 
colon (n=2) or both (n=4). Of the 36 patients with nondiagnostic CE, the SB was reported as 
normal in 28. Three patients in this subgroup had additional non-SB findings (which were 
considered insignificant): 2 in the stomach and 1 patient with findings in both stomach and 
colon. The indication for CE was melaena in 59 patients and IDA in 16. Patients with 
nondiagnostic CE findings were significantly more likely to have undergone CE for melaena 
rather than IDA, compared to patients with significant CE findings (p=0.03). Table 6.4 









Table 6.4: Breakdown of CE findings in Group 2 
Significant CE Findings (n=39) 
Type of findings Number of patients (%) 
AVM/angiodysplasia 13 (33.3%) 
Free blood/active bleeding 11 (28.2%) 
Enteropathy, ?NSAID/other medication 
related 
1 (2.6%) 
PHE including SB varices 5 (12.8%) 
Significant-appearing SB lesion e.g. polypoid 
masses 
3 (7.7%) 
Normal SB but findings elsewhere in gut 6 (2 gastric findings; 4 caecal/colon 
bleeding) (15.4%) 
Nondiagnostic CE Findings (n=36) 
Type of findings Number of patients (%) 
Normal capsule endoscopy 28 (77.8%) 
AVM not deemed clinically significant 6 (16.7%) 
Nonspecific changes/findings e.g. mild 





There were 12/75 (16.0%) gastric findings missed by initial UGIE. Ten patients underwent 
repeat UGIE. Six UGIEs were done to target lesions seen on CE (3 of these were push 
enteroscopies to reach the duodenum). 11/75 (14.7%) patients  had new colon findings; all 
these findings were arteriovenous malformations (AVMs) and/or colonic bleeding. Overall in 
this group, 25 patients underwent colonoscopy following CE. Seven colonoscopies were done 
to target lesions seen on CE while the remainder were carried out in patients experiencing 
continued bleeding or symptoms. 14/25 colonoscopies found likely causes for the patients’ 
presentations; notably, one patient was found to have a colon adenocarcinoma. In the 
patients with negative colonoscopies, most were managed conservatively with spontaneous 
resolution of bleeding in 6; in 2 patients repeat UGIE found the likely sources of blood loss. 
One patient had CT colonography following normal CE with no cause found.  
Nine patients underwent DBE to further investigate discrete lesions seen on CE (n=3), 
manage SB angioectasias (n=3) and further investigate/manage an area of active SB bleeding 




6.3.4 Comparison of colon investigations per episode of GI bleeding between the 
two groups 
In Group 1, a total of 103 colon investigations (colonoscopies and CT colonographies) were 
performed for 95 inpatient episodes of suspected small bowel bleeding, giving a rate of 1.08 
colon investigations per episode.  The overall diagnostic yield of these colon investigations 
was 3.9%. Using the alternative approach in Group 2, 26 colon investigations were performed 
for 75 inpatient episodes of suspected small bowel bleeding, i.e. 0.35 colon investigations 
were carried out per episode. The diagnostic yield in this group was 53.8%. 
 
6.3.5 Length of time between admission and CE 
Examining only data from patients admitted for GI bleeding (excluding elective admissions 
and patients with unrelated initial presentations who developed GI bleeding during their 
hospital stay), patients in Group 2, undergoing CE following negative UGIE only, had 
significantly shorter mean times from admission to CE compared to patients in Group 1 
(5.08±3.80 vs 6.38±3.80 days; p=0.02) and shorter overall admission length (10.5±9.58 vs 
12.5±11.4 days; p=0.04). This was despite patients in Group 2 being more symptomatic of 
blood loss at the time of admission, including a greater proportion of patients displaying 
haemodynamic compromise when admitted (14/75 patients in Group 2 vs 4/95 patients in 






 6.4.1 Impact on admissions 
In this study, the earlier use of CE for inpatients with melaena or IDA, following negative 
UGIE, reduces the need for subsequent colonoscopy and shortens admission times. Previous 
data from Singh et al36 in a group of 144 inpatients has shown that the earlier use of CE (within 
3 days of admission) was associated with higher diagnostic yield, rates of therapeutic 
intervention and decreased length of stay. Similarly, the patients who underwent CE earlier 
in the diagnostic pathway also had a significantly shorter mean length of stay by about 2 days 
(p=0.04). This translates to potentially significant cost savings or at least increased patient 
turnover and therefore capacity, especially important in large hospitals with high patient 
caseload. In a 2006 study by Marmo et al203, soon after the introduction of commercial CE, 
patients undergoing CE for obscure GI bleeding (OGIB) required a mean of 1.7 hospital 
admissions to reach a positive diagnosis, with a mean of 15.5 days of hospital stay; 42% had 
more than one colonoscopy; 44.6% had 2 or more UGIEs. Hospital admissions were the 
biggest cause of resource utilisation in their group of patients, followed closely by 
colonoscopies and UGIEs. It is however acknowledged that cost-savings would vary between 
countries and healthcare systems as the cost of CE may not be adequately reimbursed at 
some centres. 
 
 6.4.2 Impact on investigative burden 
The reasons for the shortened length of stay in patients in Group 2 could be related to the 
additional time required to perform both upper and lower GI endoscopies before making the 
decision to proceed to CE. Therefore, the early use of inpatient CE was useful in guiding the 
choice of the next most appropriate route of investigation or management, as well as aiding 
the decision whether to proceed with these investigations and interventions urgently or 
following discharge. Similarly, in previous studies where CE was used acutely or semi-acutely 
to investigate GI bleeding (Table 6.5), CE findings showed good correlation with subsequent 
UGIE where CE was performed as a first-line investigation before any other 
endoscopies12,13,204–206; CE carried out after endoscopic imaging was effective in directing the 
subsequent route of investigation11,126,207–211. 
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These findings are corroborated by this study. Patients in Group 1 underwent 3.13 as many 
colon investigations per admission for IDA or OGIB compared to those in Group 2; however 
in Group 2, the use of CE earlier in the diagnostic pathway increased the DY of the resulting 
colonoscopies. Moreover, no adverse outcomes related to colon pathology were reported in 
those patients who did not have colon investigations following CE. Notably, our study reports 
a higher completion rate with 6 incomplete CEs and only 2 retained capsules in 170 inpatient 
CEs, compared to previously-quoted inpatient completion rates of 50% by Dunnigan et al40 
and 68.6% from Yazici et al39. This therefore implies that in selected patients with IDA or 
melaena, without frank rectal bleeding or other such signs or symptoms suggesting lower GI 
tract pathology, CE could be used as a diagnostic or screening tool following initial UGIE, 
allowing completion colonoscopy to be carried out on a less urgent, outpatient, basis. The 
results of CE were able to assist clinicians in determining the next most appropriate 
investigation, with no missed diagnoses in our group of patients. Overall this would help to 
optimise resource use and relieve some pressure on already overburdened systems, 
especially in the NHS. 
The advantages of such an approach are appealing as a significant proportion of patients with 
GI bleeding or suspected GI bleeding have been shown to require multiple investigations. 
Woodward et al conducted an analysis on the length of endoscopic workup in a large group 
of 451 470 patients presenting with GI bleeding212. A quarter of these patients required more 
than one procedure to investigate and/or manage GI bleeding, with an average of 2.4 
procedures per patient. In particular, patients with anaemia were the least likely to be 
managed with a single procedure, with 20 and 21% of these patients requiring further UGIEs 
and colonoscopies respectively. Similarly, in a 2015 study, Sonnenberg modelled test 
sequences in patients with GI bleeding, and found an average of 2.7 procedures performed 
per patient, with a significant 5% of patients requiring more than 6 procedures213. 
An alternative approach to CE is for patients with ongoing GI bleeding to undergo repeat 
UGIE and colonoscopy; this would be supported by the incidence of “missed” upper and 
lower GI findings seen in our group. This approach is in line with work by  Fry et al214, but on 
the other hand is not suggested by the current guidelines, and would be limited by increased 
investigative burden and poor patient acceptability. Furthermore, the current convention of 
performing colonoscopy before CE is based on older, possibly now less-supported data that 
suggest the small bowel is the bleeding source in 10% of GI bleeding20. With the technological 
advances now available, it could be suggested that the increasing accessibility of CE as a 
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diagnostic test is combined with comprehensive clinical assessment to ensure an appropriate 
and timely choice of investigation for patients with GI bleeding. 
 
6.4.3 Limitations 
Limitations of this study stem largely from its retrospective design including missing data, 
dependence on good prior record-keeping and the possible effects of advances in CE 
technology since its introduction to clinical practice. However, although image quality may 
have improved over the study period, the main finding of concern in patients with GI bleeding 
is the localisation of blood within the GI tract rather than detailed lesion definition; this is an 
obvious finding where technological improvement may not have had as great an impact. 
Furthermore, our centre’s data date from 2005, when CE had already been approved for 
conventional clinical use, with acceptable image quality from the first models which we had 
used. Similarly, our centre had started using PEG for bowel preparation at an early stage, 
almost from the beginning of the capsule service, even though official guidelines had not 
been standardised then; most of the patients in our group received similar bowel preparation 
throughout the study period. 
Another limitation stemming from the retrospective study design is that the choice of 
investigative pathway and CE timing in our patients was determined by consultant 
preference. Despite this, the demographics and admission data suggest that the two groups 
were comparable. Given that melaena was more often the indication for CE in Group 2, our 
results would also suggest that such patients with melaena and negative UGIE are more likely 
to benefit from earlier use of CE. Although this approach seems logical, in routine clinical 
practice, most centres currently reserve the use of CE until a negative colonoscopy has 
occurred. Furthermore and despite the recognised disadvantages of a retrospective study, 
such a study has the benefit of a large patient group, longer follow-up times and accurate 






Table 6.5: Summary of previous studies on use of CE in the acute to semi-acute setting 
Authors, 
Yearref 











of negative CEs 
Follow-up period 
and outcomes 



















49 Endoscopy: 30 
(26 PE/DBE) 







6 patients rebled 
Rauf et al, 
2014208 
(abstract) 
Single centre 25 (100%) NS Acute OGIB Negative 
bidirectional 
endoscopy 
NS 24 APC: 5 
Surgery: 4 
Conservative: 16 












































within 48h of 
presentation 
16 All underwent 
DBE: CE changed 
approach in 3 
patients 
(DY 16/16) 
0 - NS 
5 rebled 







20 (95%) PillCam®SB2 Malaena or dark red stools, 
haemodynamic instability, 
Hb drop >2g/dL, 
UGIE only 9.8h to UGIE 
(mean) 












transfusion >2 units 
RCC/day 
(Excluded: haematemesis, 
fresh rectal bleeding) 
 





47 (97.9%) PillCam®ESO2 Haematemesis and/or 




None CE within 12-
24h 









12 (100%) PillCam®ESO2 Malaena, haematemesis, 
haemodynamic instability 
(Excluded: Haematemesis 
<2h before presentation, 
too unstable) 
None NS 8 UGIE 
(DY 8/8) 
4 UGIE 








24 (100%) PillCam®ESO2 Malaena, haematemesis 
(Excluded: Haemodynamic 
instability) 













83 (100%) PillCam®ESO Malaena, haematemesis 
(Excluded: too unstable) 




42 UGIE  
(DY 21/42) 
NS 
4 patients rebled 
















No rebleeding. 1 
patient with 
negative CE later 
had gastric ulcer 












35 (100%) NS Acute overt OGIB NS NS 21 Enteroscopy: 10 14 NS NS 
No severe 
complications 




In conclusion, inpatient CE for IDA or melaena had a diagnostic yield of 52.3% at our centre. 
In such patients, the use of CE earlier in the investigative pathway significantly reduced the 
number of urgent inpatient colonic investigations performed, without compromising clinical 
outcomes in our study cohort. This has the potential to improve the patient experience by 
reducing the number of negative invasive procedures, and by allowing further investigations 
such as completion colonoscopy to be carried out at a later date or admission. Following on 
from this, this study found that the earlier use of CE also shortened hospital stays. The 
findings inspire confidence in the earlier use of CE in inpatients with IDA or melaena in the 







Chapter 7 Role of CE in young patients with IDA 
The previous chapter has shown that the timing of CE examination in the diagnostic pathway 
for SBB can be better utilised to improve diagnostic yield and patient outcomes. In this next 
chapter, I aim to examine how judicious patient selection can also improve the clinical utility 
of this mode of investigation. 
 
7.1 Introduction 
Previous CE studies have shown that the aetiology of GI blood loss differs with patient 
demographics. Young patients – defined in this work as those aged 50 years and below – are 
more likely to bleed from SB malignancies, Dieulafoy lesions, Meckel’s diverticuli diverticula, 
polyps or Crohn’s Disease (CD). Conversely, those older than 40 are more likely to have 
angioectasias or non-steroidal anti-inflammatory drug (NSAIDs)-induced ulceration27–29.  
Therefore, although young patients represent a small proportion of patients undergoing CE, 
previous data from our tertiary care centre has shown that they are more likely in the event 
of a diagnosis to have significant diagnoses including SB tumours28. Moreover, only a couple 
of studies focusing on young IDA patients undergoing SB evaluation are available to date28,29. 
This retrospective study aimed to estimate the DY of CE for SB pathology – in particular, the 
prevalence of SB neoplasia – in a large cohort of young patients (age ≤ 50 years) with IDA and 
negative bidirectional GI endoscopy. It also aimed to assess possible predictive factors 






 7.2.1 Patient selection 
This was a retrospective study. High-volume SBCE providers (> 100 CE cases/ year) were 
invited to contribute data on consecutive patients undergoing SBCE between 2010-2015. 
These centres were invited from the ESGE SB Working Group’s research network. 
Inclusion criteria were: age 19-50 (inclusive), presenting with IDA based on the World Health 
Organization criteria (Hb < 13 g/dL in men and < 12 g/dL in women, with evidence of iron 
deficiency: MCV < 80 or ferritin < 12-15 µg/l), and negative upper and lower GI endoscopy 
evaluation. 
Exclusion criteria were: history of previous (or ongoing) obscure-overt GI bleeding (to 
homogenize the included patients), patients referred for SBCE for indications other than IDA, 
or presence of any comorbidity that could also cause IDA (e.g. known inflammatory bowel 
disease, coeliac disease, end-stage renal failure, prosthetic heart valve). Only women with 
recent complete gynecological evaluation (to exclude any cause of excessive gynecological 
blood loss) were included.  
 
 7.2.2 Data collection 
Structured data collection questionnaires were sent to all participating centres. The data 
collection form which was sent out is shown in Appendix I and the participating centres are 
detailed in Appendix II. Data were collected on patient demographics (age, gender), medical 
history including weight loss and comorbidities, indications for CE, investigations performed 
before CE [Hemoglobin(Hb) at time of SBCE and lowest recorded value if available, mean 
corpuscular volume (MCV), GI endoscopies/cross-sectional imaging, duodenal 
biopsies/coeliac serology], medications (NSAIDs, antiplatelet agents, warfarin/heparin), 
findings, final diagnosis and outcomes (if known or if followed-up within the study period). 
CE videos were analysed by local readers as part of standard clinical care; no further central 
CE reading was performed. 
Local investigators were asked to categorise findings according to their clinical relevance 
using the Saurin score93. CE examinations were deemed positive when containing at least one 
P2 SB finding, i.e. a finding which could explain symptoms and/or guide further workup. For 
the purpose of further analysis, P2 CE findings were eventually categorized as: neoplastic or 
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non-neoplastic but clinically significant. In order to allow for variations in practice between 
participating centres and to accommodate missing data, a minimum data set was defined for 
inclusion: patients had to have had Hb at time of SBCE, MCV, negative bidirectional GI 
endoscopies and CE results. 
All patient identifiable data were anonymized during collection. No specific ethical approval 
needed to be obtained as all data were collected during routine patient care. 
 
 7.2.3 Statistical analysis 
Continuous variables are presented as means (SD) or medians (IQR), as appropriate. 
Categorical variables are presented as numbers (%). Due to the number of variables, CE 
findings were analyzed by multivariate logistic regression using 5 multiple imputed datasets 
to adjust for missing values of ferritin and lowest recorded Hb in some patients. This allowed 
maximal use of data while minimizing bias from missing values215,216. Further variable 
selection was done using backwards elimination. For model comparison, the log likelihood 






 7.3.1 Included patients 
Cases were collected from 18 centres in 12 countries. Data on 389 patients (262F/127M; 
mean age 39.4±9.3 years) were scrutinized. 220 patients (122F/98M; mean age 40.5±8.6 
years) had sufficient data for inclusion in the final analysis, as defined by the minimum data 
set (Figure 8.1). The patients’ clinical characteristics are summarized in Table 8.1. At 
presentation, the mean Hb for the patient group was 9.27±2.36 g/dL, mean MCV was 
71.54±9.59 fL and mean ferritin was 13.16±29.65 µg/L. 
 















169 excluded (43.4%) 
Missing data: bidirectional GI endoscopy results, information 
on Hb/MCV at time of diagnosis/referral, gynaecological 
examination (where appropriate), negative coeliac serology 
and/or biopsies to rule out coeliac disease  
389 patients collected 
(262 F/127 M; mean age 39.4±9.3 years) 
Final analysis: 220 patients 







Table 7.1: Characteristics of included patients (n = 220) 
The number of patients is specified where data was not available for all patients. 
Demographic details 
Gender 122 F/98 M 
Age (mean ±SD), years 40.5±8.6  
Past medical history 
Gastrointestinal disease n(%) 38 (17.3%) 
Cardiovascular disease n(%) 25 (11.4%) 
Previous malignancy n(%) 5 (2.3%) 
Renal disease n(%) 2 (0.9%) 
Other past medical history n(%) 
e.g. diabetes, rheumatological conditions 
65 (29.5%) 
Family history of GI malignancy n(%) 23 (10.5%) 
Characteristics at presentation 
Patients presenting with weight loss n(%) 17 (7.7%) 
Hb at presentation (mean±SD) 9.27±2.36 g/dL 
Lowest Hb recorded (n = 193) (mean±SD) 8.53±2.2 g/dL 
MCV at presentation (mean±SD) 71.54±9.59 fL 
Ferritin at presentation (n = 181) (mean±SD) 13.16±29.65 µg/L 
Relevant medications n(%) None: 201 (91.4%) 





More than 1 medication: 2 
Prior imaging investigations 
Patients previously investigated with CT abdomen n(median; 
range) 
60 (1; 1-3) 
Patients previously investigated with MRE n(median; range) 15 (1; 1-3) 
Abbreviations: CT computed tomography, Hb haemoglobin, MCV mean corpuscular volume, MRE magnetic 






7.3.2 Diagnostic yield of CE in young patients with IDA 
Among the 220 patients, 71 had a positive CE (DY 71/220; 32.3%). Subsequently, patients 
with positive CE were divided according to final diagnosis into 2 groups (Figure 7.2): patients 
with neoplastic SB pathology (10/220; 4.5%), and non-neoplastic albeit clinically significant 
CE findings (61/220; 27.7%). The most common non-neoplastic but significant findings were 
SB angioectasias (22/61) and SB Crohn’s disease (15/61) (Table 7.2). In total, 17 patients 
reported weight loss at presentation. Two of this group eventually had neoplastic pathology 
and 9 had non-neoplastic but significant findings, i.e. 2/10 (20%) of patients with neoplasia 
presented with weight loss, compared to 9/61 (14.8%) of patients with non-neoplastic 
findings and 6/149 (4%) of patients with normal or insignificant findings. In the patients with 
neoplasia, 6/10 had undergone CT or MR imaging prior to CE with no pathology yield (hence 
the investigation with CE). 22/61 of patients with significant non-neoplastic pathology, and 





















Table 7.2: CE small bowel findings in study group 
Type of findings Number of patients (%) 
Details below 
Neoplastic 10 (4.5%) 
Malignant neoplasia: 4 adenocarcinoma, 3 GIST, 1 lymphoma 




22 angioectasias, 15 Crohn’s Disease, 5 nonspecific inflammation, 5 
ulcers, 5 NSAID enteropathy, 9 others (2 Meckel’s, 1 inflammation due 
to rheumatoid arthritis, 1 coeliac, 1 strictures, 1 Dieulafoy lesion, 1 
hereditary haemorrhagic telangiectasia, 1 pinworms, 1 mucosal bulge) 
Normal/ minimal and not 
clinically significant 
149 (67.7%) 






 7.3.3 Predictors of significant SB pathology 
All possible predictive factors included were subjected to variable selection to identify the 
best predictors of significant SB pathology (both neoplastic and non-neoplastic). These were: 
ferritin, MCV, presence of weight loss and use of antiplatelet pharmacologic agents 
(supplementary material). On multivariate analysis (Table 7.3), lower MCV was associated 
with clinically significant SB pathology (OR 0.96; 95%CI 0.92-0.99; P=0.03), i.e. the odds of 
diagnosing significant SB pathology in CE were increased 4% for every unit of decrease in 
MCV. Furthermore, the presence of weight loss at clinical presentation increased the odds of 
significant SB pathology 3.85 times (OR 3.85; 95%CI 1.31-11.13; P=0.01). Lastly, this model 
suggests a possible association between the use of antiplatelet medications and the presence 
of significant findings (OR 3.74; 95%CI 0.765-18.313; P=0.10); however, due to the small 
number of patients receiving this specific pharmacological treatment, no valid conclusion can 
be drawn. 
 
Table 7.3: Predictive factors for significant SB findings in young patients with IDA 
Variables in initial 
model 
OR SE(logOR) Pr(>|t|) 95% CI 
(Intercept) 2.226 1.26 0.530 0.188-26.301 
Weight Loss (Y/N) 3.857 0.55 0.010 1.313-11.336 
Initial MCV 0.961 0.02 0.030 0.924-0.999 
Antiplatelet use 3.743 0.81 0.100 0.765-18.313 
NSAID use 2.586 0.94 0.310 0.410-16.320 
Lowest Hb 1.150 0.09 0.120 0.964-1.372 
Abbreviations: CI confidence interval, Df degrees of freedom, Hb haemoglobin, MCV mean corpuscular volume, 






 7.3.4 Patient outcomes 
In this cohort, 136/220 patients had resolution of IDA on follow-up (which was variable 
between centres). At the time of writing, 18/220 were lost to follow-up. Table 7.4 details 
outcomes for this patient group following CE. Seven of the 10 patients diagnosed with 
neoplasia had resolution of IDA following surgical management. Of the 3 in whom IDA did 
not resolve, 2 were diagnosed with adenocarcinoma and 1 had been diagnosed with a 
hamartoma. 
 




up was available) 
Resolution of IDA No Resolution 
Active treatment Conservative 
management 
only 





7: all surgical management - 2: further enteroscopy (1 for 
retrieval of retained capsule, 
1 for biopsy) 





14: treatment for CD 
10: further enteroscopy 
4: repeat ileocolonoscopy 
2: repeat CE 
1: repeat UGIE 
5: surgical management 






2: repeat ileocolonoscopy 
1: Meckel’s scan 
82 2: further SB evaluation 
1: repeat CE 
1: repeat UGIE and 
ileocolonoscopy 
45 
Abbreviations: CD Crohn’s Disease; CE capsule endoscopy; SB small bowel; UGIE upper gastrointestinal endoscopy 
 
In the group of patients with non-neoplastic but clinically significant pathology, 44/61 
(72.1%) had IDA resolution on follow-up. Eighteen of these 44 patients required further GI 
endoscopy (UGIE, ileocolonoscopy, repeat CE and/or deep enteroscopy including push 
enteroscopy and double-balloon enteroscopy). Five patients required surgical management: 
2 underwent resection of Meckel’s diverticulae diverticula, 1 required surgery for removal of 
the retained capsule, 1 had haemorrhoids banded and 1 underwent SB resection for CD. 
Thirteen out of 44 patients were managed conservatively; 10 had angioectasias, 2 had 
nonspecific SB inflammation and 1 had pinworms. Thirteen out of 61 patients with non-
neoplastic but clinically significant pathology (21.3%) did not have resolution of IDA on 
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follow-up. Seven of these 13 patients had angiodysplasias. In this group, 9/13 had undergone 
further SB evaluation by deep enteroscopy.  
85/149 (57.0%) patients with no significant pathology on CE had resolution of IDA on follow-
up. 82 of these patients were managed conservatively; 2 underwent further ileocolonoscopy 






 7.4.1 Causes of SB blood loss in young patients with IDA 
A significant proportion of patients with IDA (approximately 30%) remain undiagnosed 
following bidirectional GI endoscopy, prompting SB evaluation23. The results of this study are 
in agreement with existing studies on the epidemiology of SB blood loss and show that 
younger patients, presenting with IDA, are at higher risk of SB neoplasia compared to older 
patients. Zhang et al found that SB angioectasias, while the most common cause of OGIB in 
patients aged >65 and accounting for 54% of cases, were present in only 9% of patients 40 
years old or less35. Likewise, only 10% (22/220) of patients in our cohort were found to have 
SB angioectasias. In contrast, about 5% of the patients in this study had SB neoplasia, similar 
to the estimated population prevalence of 3-9%30,31. Previously, it has been reported at our 
centre that sinister or significant pathology appears in 25% of patients below 40 years old 
but only 7.5% of patients over 40 years28.  
A study by Sidhu et al demonstrated angioectasias in 10% of patients younger than 50 years 
old who underwent CE for IDA, and SB tumors in 3% of the same patient cohort29. 
Interestingly, SB angioectasias are known to occur more frequently alongside other 
comorbidities including cardiovascular disease, chronic kidney disease and/or chronic 
respiratory conditions; consequently, SB angioectasias may be less common in younger, fitter 
patients such as our group219. Therefore, this large multicenter study underscores the 
importance of having a high index of suspicion in young patients presenting with IDA. 
  
7.4.2 SB neoplasia 
Small-bowel neoplasia was the diagnosis considered the most significant in this group of 
young patients. Of the 10 patients from this cohort diagnosed with neoplasia, 8 had 
malignant histopathology.  According to US and UK data, carcinoid tumors and 
adenocarcinomas are the most common SB neoplasias32,33. The UK data also show an 
increasing incidence of SB tumors since the 1980s33. The prognosis of SB malignancy remains 
poor; for example SB adenocarcinoma still has a 5-year survival of less than 30%32. This could 
be due to factors such as location of the malignancy – significant proportions of these SB 
tumors were located in the ileum, thus out of reach of conventional endoscopy33 – and the 
resulting diagnostic delay 220. Modlin et al found patients with SB carcinoid tumors were more 
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likely to have disseminated disease at diagnosis compared to gastric carcinoids. The same 
study showed minimal change in survival rates for carcinoid tumors over the past 50 years, 
implying failure to identify these lesions in a timely manner, or a lack of information to guide 
effective treatment221. 
 
 7.4.3 Predictive factors for significant SB findings 
Notably, only a small proportion of patients in our group had weight loss as a symptom at 
the time of presentation and only 2 out of 10 patients with neoplastic pathology experienced 
weight loss. This emphasizes the minimal or nonspecific symptoms which SB malignancies 
initially present with30. On the other hand, a larger proportion (20%) of the group with 
neoplastic diagnoses reported weight loss compared to patients with significant non-
neoplastic pathology (14.8%) and those with normal CE results (4%). These differences 
suggest that young patients presenting with weight loss should be investigated more 
extensively and earlier. 
To the best of my knowledge, there are few studies attempting to quantitatively correlate 
risk of significant SB findings with red cell indices as markers of IDA. As MCV decreased, there 
appeared to be a proportionate increase in the likelihood of SB tumors. In anaemic patients 
the probability of IDA increases with decreasing MCV222. This could be related to the duration 
of IDA, or because the anemia had failed to resolve over a period of time thus indicating 
ongoing or progressive pathology. For such patients with more severe IDA, the current UK 
guidelines suggesting 1-3 months of empiric oral iron replacement therapy following 
negative bidirectional endoscopy may cause further diagnostic delay. 
 
 7.4.4 Limitations 
Limitations of this study include its retrospective study design, meaning that clinical data 
were incomplete for several patients (almost half in the included cohort). This could have led 
to some overestimation of results. This potential effect has been minimized as far as possible 
using multivariate analysis as detailed. Secondly, many of the participating centers were high-
volume or tertiary referral centers, which would therefore have taken a disproportionate 
number of complex patients or those suspected of having sinister pathology. Finally, this 
study used MCV as a marker of iron deficiency in anemic patients although drawbacks exist 
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to the use of MCV to quantify iron-deficiency. Other red cell indices such as mean cell 
hemoglobin (MCH) (i.e. markers of hypochromia rather than microcytosis) may correlate 
better with severity of IDA than MCV223. Current guidelines state that MCV alone is not 
enough to make a diagnosis of IDA and other parameters, namely ferritin, should be used to 
assess iron status222 as ferritin correlates well with total body iron stores and is a better 
marker of iron deficiency; low MCV occurs only in the later stages of iron deficiency224. Data 
on ferritin was not available for all the patients in our group, and MCV was used in this study 
due to its widespread use and availability. Both markers are less reliable in elderly and/or 
hospitalized patient populations  several other  comorbidities e.g. inflammation and anemia 
of chronic disease225 but may be more reliable  in the younger group that overall has a lower 
rate of comorbidities. 
 
7.5 Conclusion 
There is a lack of data on the outcomes for patients with unexplained IDA, and existing 
studies imply that the current management of IDA alone is often incomplete or 
inadequate226. This study has attempted to address some of these gaps so as to improve 
patient care. In patients ≤50 years old presenting with IDA, the overall diagnostic yield of CE 
for significant SB findings was 32.3%. Around 5% were diagnosed with SB neoplasia. In this 
cohort, lower MCV and weight loss were associated with higher risk of a diagnosis of 
significant SB neoplasia findings. Therefore, in young patients with certain clinical features 








Chapter 8 Effect of CE image visualisation quality on diagnostic certainty 
As established in the earlier chapters of this thesis, CE is at present an entirely visual 
diagnostic tool which is highly reliant on image quality. This chapter therefore aims to 
investigate how image quality affects diagnostic certainty for CE readers. 
 
8.1 Introduction 
Image quality is in itself dependent on several factors ranging from hardware (camera ability), 
software (image processing ability) and patient factors including bowel preparation and gut 
motility. However, although there is a paucity of evidence by way of peer-reviewed studies, 
it is perhaps intuitive that optimising visualisation quality should have a positive effect on 
diagnostic accuracy and certainty. 
Previous work has been limited by the lack of a widely-accepted method for quantifying 
visualisation quality in CE reporting. A few studies have been carried out attempting to 
standardise the grading of SB preparation and to establish a universal grading score, but none 
so far have been widely adopted in clinical practice193. Efforts have also been limited by the 
wide variety of proprietary capsule reading/reporting software on the market, which 
hampers attempts at standardisation.  
In this study, the contribution of various image parameters to visualisation quality and their 
effect on certainty of diagnosis of small bowel lesions is examined. The use of image 
parameters may aid standardisation in the reporting of small bowel visualisation quality as 







8.2.1 Phase 1: initial pilot study 
The initial pilot study aimed to identify parameter thresholds or landmarks at which CE 
images became inadequate for diagnostic purposes. Five clear CE images of common SB 
pathology were selected: a P1 angioectasia, P2 angioectasia93, ulcer, aphtha and malignant 
polyp (as a representative of neoplastic lesions). These images were deemed “clear” and 
unambiguous by two expert CE reviewers at our centre, and standardised to a resolution of 
320x320 pixels (px). Each image was processed for 3 parameters using GIMP2 image 
processing software, an open-source graphics editor compatible with several operating 
systems and image formats (www.gimp.org): 
(1) Opacity: The colour of the mask filter was colour-matched to that of luminal content 
from a clearly poorly-prepared CE video, to simulate the effects of large amounts of 
luminal debris. 9 processed images were obtained using colour masks overlying the 
original “clear” image, set at opacities of 10-90% in 10% increments. 
(2) Blurriness: A Gaussian blur was chosen to simulate the effects of movement, 
therefore approximating both poor focus and the effects of rapid movement of the 
capsule through the bowel. 9 processed images were obtained using blur radius 1-
10px in 1px increments. 
(3) Contrast:  Contrast was chosen as a parameter as this adjustment is common across 
most commercial capsule reporting software. Images were processed from -50% 
contrast to +50% in 10% increments. The images obtained are shown in Figure 8.1. 
The sheer number of images resulting from this systematic stepwise image modification, 
even with only five original images, was the reason for an initial pilot study. A smaller group 
of reviewers was recruited compared to the second phase, as each reviewer had to agree to 
sift through this large number of images generated, whereas the second phase would focus 





Figure 8.1: Panels showing range of images used for pilot study. (a) Opacity; (b) Blur radius; (c) Contrast 
(a) Image set, with original images, altered for increasing opacity 
Original       10%          20%           30%          40%          50%          60%          70%           80%          90% 
136 
 
(b) Image set altered for increasing blur radius 
    1px           2px          3px          4px          5px           6px         7px           8px         9px          10px 
137 
 
(c) Image set altered for decreasing and increasing contrast 
 
   -50%        -40%       -30%       -20%        -10%       +10%       +20%      +30%       +40%       +50% 
138 
 
A group of 9 expert readers from several centres were then asked to review the resulting set 
of 9 original and 190 processed images, which were presented to them in random order using 
an online survey platform. For each image, reviewers were asked to evaluate whether it was 
adequate (or not) for diagnostic purposes, i.e. from the image, could they be sure of the 
diagnosis. Based on the percentage of reviewers deeming each image adequate or otherwise, 
four points where perception of image quality changed significantly were determined for 
each parameter. Appendix III shows the online survey platform which was used to gather 
data for this phase of the study. 
 
8.2.2 Phase 2: Validation 
Common SB lesions were classified into three main types: vascular, inflammatory and 
neoplastic/possibly malignant. Therefore three further sets of 9 clear images each were 
obtained; all these images were deemed “acceptable” by the same two expert CE readers as 
above. The images of vascular lesions were obtained from the same set as used in a recent 
study by Leenhardt et al, who have established an expert consensus on the nomenclature of 
vascular lesions seen on SBCE227; this was an additional step to ensure that the starting 
images for this phase of the study had already been deemed “clear” by a group of expert CE 
readers based across multiple centres. 
Based on the findings of the pilot study, each of the images in this new set was processed for 
4 points per parameter as above. This resulted in a second set of 27 original and 108 adjusted 
images, some of which are detailed in Figure 8.2. 20 experienced-expert CE readers reviewed 
the resulting images using an identical setup to the first phase. Results from each group of 
images (i.e. each type of pathology) were pooled and the mean percentages of readers 
finding each image adequate, with standard deviations (SD), were used to examine results. 








Figure 8.2: Examples of the original images used in Phase 2. Top row: vascular lesions; middle 
















8.3.1 Phase 1: Pilot study 
For image opacity, both angioectasias and the neoplastic lesion were considered adequately 
visualised below 40% opacity whereas the threshold was lower for both the ulcer and aphtha 
(10% opacity). Increasing blur radius significantly impacted the acceptability of images for 
reaching a diagnosis with confidence; for most images, blur radius 3px was the threshold for 
adequate visualisation but even 1px of blur radius decreased the visualisation quality of the 
aphtha image. The aphtha image was also affected the most by decreased contrast; 
conversely the ulcer was deemed more inadequately visualised with higher contrast. The 
other images were generally adequately visualised at ±10% contrast. 
Figure 8.3 shows the percentage of expert CE readers who found each image adequate for 




Figure 8.3: Percentage of readers who found each image diagnostically adequate. (a) Opacity; 









































































































































































8.3.2 Phase 2: Validation of results from pilot study 
In vascular and inflammatory lesions, diagnostic certainty was least affected by increasing 
image opacity, requiring opacities >90% before most readers considered images inadequate 
for diagnosis. The greatest negative effects of image opacity were seen in neoplastic lesions 
where significantly fewer readers found images adequate at >50% opacity. In general, the 
spread of responses as demonstrated by the error bars in the images in Figure 8.4 as well as 
standard deviations in Table 8.1 was greater for both vascular and inflammatory lesions 
compared to neoplastic ones. 
Similar results were obtained with increasing blur radius, simulating the effects of motion 
blur from segments of rapid small bowel transit and poor focus. The proportions of readers 
finding vascular and inflammatory images adequate for diagnosis did not drop significantly 
at wider blur radii, while the proportion who found images of malignancies diagnostically 
adequate dropped at blur radius 6px. Once again, the spread of responses was greatest in 
the set of vascular lesions and responses were most cohesive for neoplastic lesions. 
Decreasing contrast had greater negative effect than raised contrast, most obvious in the set 
of neoplastic lesions. Responses from the group of reviewers were markedly less cohesive 





Table 8.1: Mean±SD of the percentage of reviewers who found images in each type of 
pathology adequate for diagnostic purposes 
Lesion type/ Parameter 
OPACITY Original     




























BLUR RADIUS Original     




























CONTRAST Original     











































Figure 8.4: Effects of altering image parameters in Phase 2, shown as median and spread of responses for each set of images. (a) Opacity; (b) Blur 
radius; (c) Contrast 
 


































































































































































































































































































 8.4.1 Effect of image parameters on CE image quality 
Current CE guidelines recommend that image quality is recorded when reporting CE21. At 
present however there are few validated scales which have been developed to quantify 
image quality in CE. Furthermore, these scales are not in wide use and have not been 
subjected to more widespread testing and adoption; they also tend to be based on subjective 
parameters193,228. This creates discrepancy and a degree of uncertainty when reporting CE, 
for both clinical and research purposes. 
Image quality is affected not only by luminal conditions but also the hardware of CE systems 
themselves. The majority of available literature concentrates on quality of bowel 
preparation229,230, perhaps because clinicians have some control over these factors. At 
present, there is little which examines the effect of hardware or software on image 
visualisation in the clinical or real-world context. Nevertheless, it is important for technology 
to be developed with the end-user in mind. Much of current CE image-processing technology 
is developed by the manufacturers and then tested by clinicians; involving clinicians in the 
development process could well be more efficient and effective. 
A few studies exist pitting different capsule models against each other, to assess the effects 
of hardware and software improvements. A 2016 study by Monteiro et al compared the 
PillCam® SB2 to SB3, finding that the improved image resolution and faster variable frame 
rate increased duodenal papilla detection rates from 24% to 42.7%231. Kim et al in 2018 
compared the PillCam® to Mirocam232. A small group of patients underwent simultaneous 2-
capsule CE. Capsule reviewers achieved an agreement rate of 70%, implying that just under 
a third of patients had different findings between the two models of capsule. In another study 
by Omori et al, the use of the 3rd-generation PillCam® SB3 was found to reduce time burden 
for both expert and inexperienced readers. The authors propose that this was due to an 






 8.4.2 Implications of results for further developments 
Therefore, this study represents a conscious attempt to “work backwards”, starting from 
images deemed adequate by expert CE readers and adjusting them in a stepwise manner 
until a point where the majority of readers felt these images were inadequate for diagnostic 
purposes. The results show that image sharpness may have more effect than opacity, 
especially in the diagnosis of potentially malignant small bowel lesions. A relatively high level 
of image opacity was “tolerated” by the group of CE readers in this study whereas blurriness 
seems to have a greater impact on visualisation quality and reviewer confidence in the 
diagnosis. Furthermore, there was greater agreement amongst the reviewers about overall 
image quality in the neoplastic images compared to vascular lesions. 
In combination with the aforementioned studies, this implies that software algorithms (such 
as adaptive frame rate) and hardware improvements (such as camera resolution) which are 
able to obtain more and sharper images, despite variations in bowel motility, would help to 
provide capsule readers with better quality images and aid diagnosis. Software which is able 
to adjust images already obtained, e.g. by sharpening images or adjusting contrast to 
improve visualisation, could also be of use. Increased diagnostic certainty based on higher-
quality capsule images could reduce reading time and therefore burden on capsule readers; 
higher quality images could further improve the development of and confidence in 
computer-aided diagnostic software. Interestingly, at present there is no “zoom” function 
available in CE – this is perhaps an area for further development and study. 
Currently, existing attempts to develop computer-based automated bowel preparation 
grading systems have been based mainly on the overall colour of frames228 or on the 
percentage of the lumen which has been obscured by debris and bubbles194,234,235. These 
approaches can work well for approximating bowel segments or detecting gross 
abnormalities such as blood in the lumen236, but do not take into account the effect of image 
sharpness and motion blur. Furthermore, the results of this study suggest that the quality of 
bowel preparation which can be tolerated differs according to clinical indication for the CE 
examination. For instance, CE carried out for suspected small bowel bleeding may not require 
as pristine a bowel lumen as one looking for the lesions of mucosal inflammation or subtle 
small bowel tumours. This appears to be the first study which specifically examines the effect 




 8.4.3 Limitations 
Limitations of this study are, firstly, related to the lack of existing data or previous work for 
comparison. Furthermore, the data set comprises only still frames, with a relatively limited 
sample size owing to the need to recruit expert CE readers and for them to critically scrutinise 
a large set of images. Fewer data points for each parameter were included in the second 
phase, using four points for each image rather than the more detailed stepwise adjustments 
made in the first, pilot phase, in order to allow for a wider range of images to be examined.  
 
8.5 Conclusion 
In this study, poor visualisation quality in the parameters examined – luminal opacity, 
blurriness and contrast – had the greatest effect on diagnostic certainty of malignant lesions. 
Therefore, this implies that software to increase contrast and sharpen images or correct for 
poor focus can be used and developed to improve visualisation quality; smart frame rate 
adaptation could also improve the number of high-quality frames obtained even with 
variations in bowel motility and transit times. Furthermore, the thoroughness of SB 
preparation is most important when CE is being carried out for suspected SB malignancy – 
greater care should be taken to obtain high-quality images for this indication. 
Future applications of this data include the potential integration of the parameters 
investigated here with computer-assisted CE diagnostic or bowel preparation grading 
software. Further studies could also examine the effects of bowel visualisation quality in 
colon CE; the contribution of image quality to diagnostic accuracy and certainty may be even 
greater in colon CE due to the increasing amounts of debris in the distal gastrointestinal tract, 








Chapter 9 Discussion and conclusions 
9.1 Summary and overall conclusions 
In this thesis, I have shown that: 
 Digital image-enhancement methods such as FICE are marginally useful for 
improving visualisation quality of capsule images; however their overall clinical 
impact and utility is limited. 
 Image selection methods such as SBI are of value in digitally identifying areas of GI 
bleeding prior to review and therefore reducing CE reading times. This does not 
compromise on diagnostic accuracy in the setting of GI bleeding and is especially 
useful in patients with active GI bleeding at time of CE. 
 The use of laxative bowel preparation improves visualisation quality of CE images but 
has not been shown to have an appreciable effect on diagnostic yield or completion 
rate of CE examination. 
 Optimising CE image visualisation quality improves diagnostic certainty. Improved 
image visualisation quality has the greatest effect when examining images of 
neoplastic, potentially malignant SB lesions (compared to vascular and 
inflammatory-type lesions). 
 CE is useful in the acute to semi-acute setting to triage and diagnose patients with 
suspected SBB, i.e. those presenting with IDA and/or melaena, negative upper GI 
endoscopy and no convincing signs of large bowel pathology. The early use of CE 
following negative initial upper GI endoscopy has the potential to defer colonoscopy 
in order to take pressure off overburdened systems and reduce the overall number 
of colonoscopies performed in such patients.  
 Younger patients (age <50 years) presenting with IDA and who have undergone 
negative bidirectional endoscopies should be particularly considered for 
early/expedited CE as they are more likely to have significant SB pathology, especially 








GI bleeding, and especially overt or suspected SBB, remains the main clinical indication for 
CE in routine practice. CE has been shown to be a useful diagnostic tool for the 
aforementioned reasons discussed in this body of work; however, the data presented here 
also suggests that it could potentially have a greater role in the semi-acute setting due to its 
ease in use, minimal invasiveness, and lesser requirement for manpower compared to 
conventional GI endoscopy. 
Certainly, CE has the potential to be used as a screening tool in patients presenting with 
suspected SBB, following negative UGIE and before proceeding to colonoscopy – such an 
approach could optimise resource use by triaging patients who should (or need not) undergo 
urgent inpatient colonoscopy, cutting costs incurred from unnecessary investigations, 
lengthy hospital stays, and sparing a proportion of patients a more invasive, unpleasant 
procedure. 
SBI software has been shown to be reliable for the identification of active GI bleeding and 
can be used to speed up the reporting process in this setting. On the other hand, FICE 
technology requires further development in order to be clinically useful – or perhaps the use 
of FICE is not the solution here, and other methods of image enhancement and selection 
should be pursued in future work. Overall, however, digital methods of image enhancement 
are only as good as the hardware allows. Future improvements to CE systems should ideally 
centre on improving hardware quality. Colour alteration with software such as FICE, blue 
mode and ALICE does not seem to be as useful for image delineation or diagnosis, whereas 
improved focus and image resolution do appear to improve diagnostic certainty. 
Where there is clinical suspicion of other non-vascular causes of GI bleeding such as SB 
tumours, more finesse is indicated in order to improve the diagnostic capability of CE 
investigation. In current clinical practice, the most reliable and controllable method to 
enhance visualisation quality is to use laxative bowel preparation. However, apart from 
patient condition and tolerance, the use of bowel preparation should also be influenced by 
the indication for CE examination, for example, considering whether the potential source of 
GI bleed is vascular, inflammatory or malignant. 
The data here suggest that the diagnostic certainty for neoplastic-appearing lesions is most 
affected by poor visualisation quality, compared to the other common “classes” of SB 
pathology. Even though the use of laxative bowel preparation improves visualisation quality 
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as perceived subjectively by CE readers, the effect on diagnostic yield is minimal. This implies 
that the value of using laxative bowel preparation lies in lesion delineation and the 
identification of pathology. Therefore, rather than focusing on achieving a pristine bowel in 
all patients undergoing CE, greater attention to bowel preparation should be given to 
patients suspected of having a malignancy or other neoplastic lesion, and conversely, the 
need for bowel preparation should also not hold up a (semi-)urgent capsule in a patient who 
is likely to have vascular lesions causing SBB. Other factors which can influence lesion 
detection and diagnostic certainty should be taken into account and certainly warrant further 
investigation; these include individual reviewers’ reading technique, capsule model and 
technology with their effects on image quality, as well as the use of repeat or “second look” 
capsule examination. 
A significant body of previous work has established that advancing age is correlated to the 
incidence of vascular lesions, whereas it has been shown here that younger patients are more 
likely to have significant SB findings on CE. Other factors found to be predictive of significant 
findings are the presence of weight loss and lower MCV as a marker of iron deficiency – taken 
together, these are factors which should prompt a more urgent referral in the young patient 
presenting with IDA. 
 
9.3 Limitations 
The specific limitations of each individual study have been discussed in the relevant chapters. 
As a whole, however, this work is perhaps mostly limited by the relatively small size of the 
field and similarly small amount of data available. As previously discussed, CE examinations 
are labour-intensive to read and interpret, therefore data collection for studies is equally as 
time consuming and labour intensive. In order to reach meaningful sample sizes, many of the 
studies making up this work had to be meta-analyses, i.e. building on existing data, 
retrospective in design so as to make use of data gathered over years to decades, and/or 
multicentre in nature. 
The use of data from several centres means there was inevitable heterogeneity between 
capsule readers at the various centres from which data were collected. Furthermore, there 
remains no standardised reading and reporting framework for CE, making this heterogeneity 
between individual readers and centres all the more obvious. In this work, I have attempted 
to address this limitation by conducting sensitivity and heterogeneity analyses in the meta-
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analyses, and by recruiting from a group of fairly similar-level expert capsule readers; 
however it must be acknowledged that these drawbacks remain and are fairly significant. 
Data collected over longer periods of time is also subject to intra-observer variation 
stemming from the learning curves of the capsule readers involved. In addition, capsule 
technology has improved over time and, as shown in this work, improved visualisation quality 
can improve diagnostic certainty and clarity. I have attempted to address this potential 
source of heterogeneity by prudent definition of data collection periods when collecting 
retrospective data from previous capsule examinations. For example, data collection for the 
multicentre study in Chapters 7 used only capsules carried out over a 5-year period from 
2010-2015 in order to capture a group of capsules which had been reported by expert 
readers already established and experienced in the field by this period of time. Similarly, the 
study in Chapter 6, based at our tertiary care centre, excluded data from the earliest capsule 
models such as PillCam®M2A, so as not to include data from capsule models with poorer 
image quality. 
 
9.4 Implications for practice 
In routine/everyday clinical practice, the following suggestions are therefore offered to 
optimise the use of CE in patients presenting with GI bleeding and to streamline their 
management: 
 In patients presenting with melaena and/or IDA, negative UGIE and in whom there 
are no symptoms suggestive of colonic pathology (such as frank rectal bleeding, 
diarrhoea or abdominal pain), an urgent CE is of diagnostic value and can be used as 
a triage tool. 
 Young patients aged 50 years old and below who present with isolated IDA and 
negative bidirectional endoscopies should be referred more promptly for CE to 
investigate the SB as SB findings in these patients are more likely to be clinically 
significant and require timely intervention. 
 The indications for CE and differential diagnoses should be evaluated on an individual 
patient basis when deciding on the mode of bowel preparation. In patients where 
there is a higher clinical suspicion of vascular causes of bleeding – or frank bleeding 
such as melaena – laxative bowel preparation may not be as vital; rather, the focus 
should be on expediting CE in order to better identify active bleeds and the location 
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of bleeding lesions in the GI tract. Conversely if pathologies such as IBD or 
malignancies are suspected to be the cause of GI blood loss, closer attention should 
be paid to achieving clear views. 
 When reading and reporting a CE examination, SBI frame-selection software is of 
particular value in locating frames where active bleeding is seen and is therefore 
useful to speed up CE reading in the acute to semi-acute setting. 
 Conversely, image enhancement software such as FICE is of limited utility, although 
it may potentially improve the visualisation of bleeding lesions. 
 
9.5 Directions for future development 
Based on the results presented in this work, the efficient, judicious use of CE as a diagnostic 
tool is a major factor contributing to its clinical utility in patients presenting with GI bleeding. 
Future developments which could improve its utility include, firstly, an emphasis on 
hardware which will allow improved image resolution and focus, i.e. to improve image quality 
and therefore diagnostic certainty. 
Building on the limitations of this work, it has certainly highlighted that much can be done to 
standardise CE reading and reporting, both for research and clinical purposes. Recently, 
Leenhardt et al have attempted to develop a structured terminology for capsule reading and 
reporting, starting with a Delphi consensus on the definition of vascular lesions227 and have 
now expended this work to include inflammatory lesions (this data remains under review at 
time of writing). There is also the need for training guidelines and competency frameworks 
for capsule reading, to ensure that qualified CE readers have attained a minimum standard. 
Previous work has already shown that not only clinicians, but nurses and clinical scientists 
can do just as well in capsule reading and reporting237. Structured reporting and competency 
frameworks can ensure that capsule reporting is more consistent and homogeneous than it 
currently is, allowing a wider range of staff to read and report capsule examinations and 
therefore even freeing up doctors to make clinical decisions such as formulating and enacting 
management plans238. At present, there is only one structured capsule reading competency 
evaluation, developed by the Mayo Clinic239; this has yet to be fully validated in a wider group 
of readers, let alone widely adopted. 
Perhaps the area with the greatest potential for development however is the field of artificial 
intelligence including machine learning algorithms and computer based or aided diagnosis. 
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These methods offer much potential to improve the efficiency of capsule examination, which 
remains limited by reading times, human factors and manpower requirements. Currently, 
the main approach adopted is to feed endoscopic images of certain types of pathology to 
various types of artificial neural networks, in order to train these networks to recognise the 
pathology of interest. Work has already emerged examining the use of such networks in 
conventional endoscopy, to identify colonic polyps63 and upper GI tract cancers240. In the 
context of CE, such studies have mainly focused on the identification of angioectasias241,242, 
and the body of data remains small. The main methods which have been used to identify 
regions or areas of interest include image segmentation and colour/pixel recognition - similar 
to the technology employed in the SBI. However at the present time these methods remain 
rudimentary and mostly image-based, working from still frames. Much further work needs 
to be done so that these techniques can be applied to long segments of video, as well as to 
establish their reliability. 
Overall, CE has proven to be a versatile mode of minimally-invasive GI investigation with 
much potential for several new indications. This thesis has attempted to establish ways in 
which the use of CE can be optimised so as to increase its clinical value, both within the limits 
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Appendix I Data collection forms sent to participating centres for the study in 
Chapter 7: Young patients referred for CE with isolated iron deficiency 
anaemia 
 
CAPSULE ENDOSCOPY (CE) IN YOUNG IDA PATIENTS: Case Report Form (CRF) 
Inclusion criteria: consecutive 19-50 years old patients undergoing CE for IDA. 
Please fulfil one CRF for each included patient. 
 
1. Center:___________________________________________________________ 
Physician filling in the CRF: ____________________________________________ 
Date: ____________________ 
 
2. Patient’s demographic data: 
Gender (M/F): ____________     Age:___________     Pts log number: ___________ 
 
3. Patient’s comorbidities 
 Cardiological (specify): _______________________________________________ 
Renal: (specify):  ____________________________________________________ 
Gastroenterological (specify):  _________________________________________ 







4. Associated signs/symptoms/family history 
Significant weight loss (>10% of initial body weight)                             o No        o  Yes   
Family history (1st degree) of gastroenterological malignancy           o No        o  Yes 
Family history (1st degree) of small bowel malignancy                        o No        o  Yes 
Previous history of malignancy           o No        o  Yes (specify:  ________________)   
History of renal failure:    o No        o  Yes (specify:  _______________________)   
History of IBD:    o No        o  Yes (specify:  _______________________)   
Presence of any other disease causing IDA:  History of renal failure:    o No        o  Yes 
(specify:  _______________________)   
Other (specify): _______________________________________________________                                                                    
 
   5. IDA history (before CE) 
5a. Length of IDA history (time-interval between IDA diagnosis and CE (months): 
________ (if less than 1 month (days):  _____) 
5b. At time of IDA diagnosis: 
Hb level:  ______    MCV: _______  Ferritin:_______  (Ferritin normal values:  
_________) 
5c. Lowest Hb value reached:  ____________ 
 
6. IDA therapy (before CE) 
6a. Patient received transfusions:  o No        o  Yes  (How many RBCU: _________ ) 
6b. Patient received iron i.v.:  o No        o  Yes  (How many RBCU: _________ ) 
 
 
- The i.v. therapy (including both transfusion and/or iron infusion) was: 
o  Temporarily effective (Hb levels were restored with therapy and 
decreased after therapy cessation) 
o  Not effective 
6c. Patient received oral iron supplementation:  o No        o  Yes   
- If so: did the trial with oral iron fulfill BSG criteria (FeSO4 400 mg bid for at 
least 1 month and 3 months after anemia correction)?      o No        o  Yes   
- The oral supplementation was: 
o  Temporarily effective (Hb levels were restored with therapy and 
decreased after therapy cessation) 
o  Not effective 
6d. Last values available before CE:   Hb________      date: __________ 
                                                                 MCV :_______     date: __________ 
                                                                Ferritin: _______   date: _________ 
 
 
7. IDA work-up (before CE):  evaluations performed 
7a. Celiac disease (CD) serology or duodenal histology to rule out CD     o No    o  Yes   
7b. Haematological evaluation:      o No        o  Yes   
7c. Gynaecological evaluation (for pre-menopausal women):  o No        o  Yes 
7d.  Faecal calprotectin:  o No        o  Yes   (if so specify level: ____________)  
7e. FOBT performed: o No        o  Yes    
(if yes: when: _________   result:  o positive    o negative) 
 
 
7f. Endoscopic evaluation before CE:    
How many EGDs were performed:  _______ 
How many colonoscopies were performed:  ____ (how many were ileo-
colonoscopies?: _____) 
How many push enteroscopy were performed:  __________ 
How many device-assisted enteroscopies were performed: __________ 
How many abdominal CT scan were performed: _________ 
How many CT- or MR-enterography were performed:  __________ 
7f1. Last gastroscopy performed (date: __________) 
o  Negative   
o  Positive   
Minor findings (findings not explaining reason for referral), please specify: 
______________________________________________________________ 
______________________________________________________________ 
Major findings (potentially explaining reason for referral) , please specify: 
______________________________________________________________ 
______________________________________________________________ 
If major findings were described on gastroscopy, please specify why the patient was 
referred for capsule endoscopy: 
____________________________________________________________________ 
7f2. Last colonoscopy performed (date: __________); with ileal intubation?  
o No        o  Yes    
o  Negative   
 
 
o  Positive   
Minor findings (not explaining reason for referral), please specify: 
______________________________________________________________ 
______________________________________________________________ 
Major findings (potentially explaining reason for referral) , please specify: 
______________________________________________________________ 
______________________________________________________________ 
If major findings were described on (ileo)colonoscopy, please specify why the 
patient was referred for capsule endoscopy: 
____________________________________________________________________ 
7f3. Radiological examinations performed (CT scan; CT- or MR-enterography); if 
positive please specify findings: 
____________________________________________________________________ 
7f4. PE or DAE performed: if positive please specify findings: 
____________________________________________________________________ 
 
8. Drug therapies (please report any therapy)  
Drug Dosage Ongoing at time of CE? 
  o Yes      o  Noo Stopped before CE (when _____) 
  o Yes      o  Noo Stopped before CE (when _____) 
  o Yes      o  Noo Stopped before CE (when _____) 
  o Yes      o  Noo Stopped before CE (when _____) 
  o Yes      o  Noo Stopped before CE (when _____) 
  o Yes      o  Noo Stopped before CE (when _____) 




8. Capsule endoscopy (CE) 
Date: ___________ 
Device used:  □  PillCam SB1, □  PillCam SB2, □  PillCam SB3,   □PillCam colon  □ 
OMOM  □ Olympus   □ Mirocam   □ Capsocam 
Procedure:         o Inpatient procedure      o  Outpatient procedure 
Complete SB evaluation (caecum reached):     o Yes      o  No 
 Capsule remained in the stomach for all the recording-
time 
 Capsule stopped because of a stricture  
 No reason explaining capsule slow transit 
 Other (specify): 
___________________________________________ 
GTT: _______________                                    SBTT: _____________________ 
SB toilette:   o poor   o fair  o  good    o excellent 
8a. Findings outside the small bowel (stomach/colon): o NO      o YES 









8b. SB findings; please specify each finding, estimated location, clinical value 
 Finding Estimated 
location 
Clinical value 
1 Vascular (_____________________) 
Inflammatory (__________________) 
Mass (_________________________) 
Other: please specify______________ 
o Duodenum 
     o  jejunum 
     o ileum 
o P0      o  P1     o P2 
2 Vascular (_____________________) 
Inflammatory (__________________) 
Mass (_________________________) 
Other: please specify______________ 
o Duodenum 
     o  jejunum 
     o ileum 
o P0      o  P1     o P2 
3 Vascular (_____________________) 
Inflammatory (__________________) 
Mass (_________________________) 
Other: please specify______________ 
o Duodenum 
     o  jejunum 
     o ileum 
o P0      o  P1     o P2 
4 Vascular (_____________________) 
Inflammatory (__________________) 
Mass (_________________________) 
Other: please specify______________ 
o Duodenum 
     o  jejunum 
     o ileum 
o P0      o  P1     o P2 
5 Vascular (_____________________) 
Inflammatory (__________________) 
Mass (_________________________) 
Other: please specify______________ 
o Duodenum 
     o  jejunum 
     o ileum 
o P0      o  P1     o P2 
 Vascular (_____________________) 
Inflammatory (__________________) 
Mass (_________________________) 
Other: please specify______________ 
Duodenum 
     o  jejunum 
     o ileum 
o P0      o  P1     o P2 




9. CE complications 
Aspiration in the airways:      o NO      o YES 
Capsule retention (CE >15 days within the patient body):         o NO      o YES 
CE excreted naturally without any therapy later than 15 days after ingestion:  
o YES without any therapy/intervention (how many days after ingestion:  
_____________) 
o  YES (how many days after ingestion:  _____________)after medical therapy 
(specify:  ________) 
o NO  (please specify how was the capsule retrieved and when:  
____________________________________________________________________) 
 
10. Management after CE 
10a. Negative CE (normal CE or P0-1 lesions) 
o   Iron supplementation and follow-up 
o   Just clinical follow-up 
o   Gynecological evaluation/hematological evaluation 
o   Further small bowel evaluation (specify with which diagnostic tool:  
___________________) 
o   Cessation of anticoagulant or anti-platelet agents 





10b. Positive CE (at least one P1 finding) 
o   Iron supplementation and follow-up 
o   Just clinical follow-up 
o   Gynecological evaluation/hematological evaluation 
o   Further small bowel evaluation (specify with which diagnostic tool and the final 
diagnosis:  
____________________________________________________________________) 
o   Cessation of anticoagulant or anti-platelet agents 
o   Other (specify:  ____________________________________________________) 
 
10c. Last visit (after CE) 
Date: _______________ 








Appendix II Centres which contributed data towards the study on CE in young 
patients with iron deficiency anaemia (i.e. Chapter 7) 
France 
Paris 6 University & APHP Hôpital Saint-Antoine, Paris 
 
Greece 
Hepatogastroenterology Unit, 2nd Dept of Internal Medicine - Propaedeutic, Research 
Institute and Diabetes Center, Medical School, National and Kapodistrian University of 
Athens, Attikon University General Hospital, Athens 
 
Ireland 
Department of Clinical Medicine, Trinity College Dublin, Dublin 
 
Israel 
Ha'Emek Medical Center, Afula 




AOU Città della Salute e della Scienza di Torino, University of Turin, Turin 
Catholic University of the Sacred Heart, Milan 
Center for Prevention and Diagnosis of Celiac Disease, Fondazione IRCCS Ca' Granda 
Ospedale Maggiore Policlinico, Milan 
Valduce Hospital, Como 
 
Malta 
Mater Dei Hospital 
 
The Netherlands 
VU Medical Center, Amsterdam 
 
Portugal 
Hospital da Senhora da Oliveira, Guimarães 
 
Romania 
University Hospital, Carol Davila University Bucharest, Bucharest 
 
Spain 
Hospital General de Tomelloso, Tomelloso 






Skåne University Hospital, Malmö 
 
United Kingdom 
Royal Hallamshire Hospital, Sheffield  












Appendix III Example of the online survey platform used for the study in Chapter 8: 



















This format continued for all images presented; images were presented in a random order 










Appendix IV Details on the experience of participating CE readers in the study on 


















Appendix V Publication resulting from the work presented in Chapter 3 
 
Yung DE, Carvalho PB, Giannakou A, Kopylov U, Rosa B, Rondonotti E, Toth E, Plevris 
JN, Koulaouzidis A. Clinical validity of flexible spectral imaging color enhancement 









Appendix VI Publication resulting from the work presented in Chapter 4 
 
Yung DE, Sykes C, Koulaouzidis A. The validity of suspected blood indicator software 
in capsule endoscopy: a systematic review and meta-analysis. Expert review of 








Appendix VII Publication resulting from the work presented in Chapter 5 
 
Yung DE, Rondonotti E, Sykes C, Pennazio M, Plevris JN, Koulaouzidis A. Systematic 
review and meta-analysis: is bowel preparation still necessary in small bowel capsule 







Appendix VIII Publication resulting from the work presented in Chapter 6 
 
Yung DE, Koulaouzidis A, Douglas S, Plevris JN. Earlier use of capsule endoscopy in 
inpatients with melena or severe iron deficiency anemia reduces need for 









Appendix IX Publication resulting from the work presented in Chapter 7 
 
Yung DE, Rondonotti E, Giannakou A, Avni T, Rosa B, Toth E, Lucendo AJ, Sidhu R, 
Beaumont H, Ellul P, Negreanu L. Capsule endoscopy in young patients with iron 
deficiency anaemia and negative bidirectional gastrointestinal endoscopy. United 
European gastroenterology journal. 2017;5(7):974-81. 
 
